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Receptor mediated endocytosis allows for the site specific delivery of exogenous 
DNA via appropriate ligand-receptor interactions. Various ligands have been used to 
target the asialoglycoprotein receptor (ASGP-R) present on the hepatocyte cell 
membrane viz. asialofeutin, asialoorosomucoid, lac-BSA, asialolactoferrin, asialo-
transferrin, asialo-ceruloplasmin and galactose. The high affinity that the receptor 
displays for the galactose sugar moiety has led to the development of several new 
galacto-lipids for the incorporation into liposomes intended for hepatocyte targeting.  
 
In this study, three cholesteryl derivatives displaying galactose units linked to the 
sterol skeleton by different spacer elements have been formulated into cationic 
liposomes with and without polyethylene glycol (PEG) accessories. The three 
galactosylated liposomal formulations were prepared using near equimolar amounts 
of MSO9 (N,N-dimethylaminopropylamidosuccinyl-cholesterylformylhydrazide) and 
DOPE (dioleoylphosphotidylethanolamine) together with the respective galactose 
derivative (at 10 mole % w/w) viz.  Cholesteryl-3β-N-(4-aminophenyl-β-D-
galactopyranosyl) carbamate; Cholesteryl (1-β-D-galactopyranosyl-1,2,3 triazol-4-yl) 
carbonate; and Cholesteryl-β-D-galactopyranoside. All liposomes displayed DNA 
binding, nuclease protective capabilities to plasmid DNA, low cytotoxicity (cell 
viability being within 60-101 %) and an increase in transfection activities, in the 
human hepatocellular carcinoma cell line HepG2, which expresses the ASGP-R 
abundantly. The results obtained correlate well with differences in the spacer element 
in the 3 galactosylated cholesterol derivatives under study and the presence and 
absence of 2 mole % DSPE-PEG2000 in the liposome formulations.  
 
Overall, it was observed that the cationic liposome containing cholesteryl (1-β-D-
galactopyranosyl-1,2,3 triazol-4-yl) carbonate (with and without PEGylated 
accessories), which was synthesised chemically using “click chemistry”, afforded the 
highest in vitro transfection activity, and may be optimised and studied further. The 
highest levels of transfection activity, in vitro, were attributed to the increased length 




targeting component. Two formulations were then subjected to in vivo studies, using 
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The concept of gene therapy emerged some 30 years ago and has enabled treatment of 
human disease at the genetic level. This therapeutic approach is superior to other 
systems that are based on merely treating the symptoms of genetic diseases 
(Motoyama et al., 2011 and Mountain, 2000).  
 
Gene therapy involves the administration of therapeutic genes (DNA) to patients, with 
the goal of enhancing the expression of specific genes or inhibiting the production of 
specific target proteins (Kawakami et al., 2008). Since both the cell membrane and 
DNA are negatively charged they tend to repel one another. Therefore carrier systems 
(also called vectors) are required for the delivery of these therapeutic genes 
(Templeton et al., 2002) into the cell. Various systems, such as viral and non-viral 
vectors, have been engineered and extensively analysed. These carrier systems seem 
to excel in some areas but still possess downfalls, in terms of their gene delivery 
efficiency (reaching their specific target cell) and their resulting transfection 
efficiency. Although viral vectors have produced greater transfection efficiency, they 
have shown the potential, to be highly immunogenic, oncogenic (chromosomal 
integration) and to lack target specificity. Non-viral vectors however, are virtually non 
immunogenic, are safe to use, easy to produce and can be engineered to achieve 
organ/tissue specificity (Zhang et al., 2010).  
 
Liposomal based gene delivery is the most frequently analysed synthetic (non-viral) 
vector, with approximately 45 open clinical trials being carried out worldwide 
(Simões et al., 2005). Liposomes are microscopic lipid bubbles which tend to form by 




liposome is a result of interactions that occur between the lipids in the solution, and 
the structure is completely dependent on the components in the solution (Karmali and 
Chaudhuri, 2007). Lipids contain a hydrophobic tail and a hydrophilic head group, 
and those that are used in the formation of liposomes, are connected by a backbone 
linker (usually glycerol). Liposomes form by separation of hydrophilic components 
from the hydrophobic components (Balazs and Godbey, 2011), resulting in the 




Figure 1.1: Basic formation of liposomes (Adapted from Balazs and Godbey, 2011). 
 
 
Lipid vesicles such as liposomes, possess an abundant array of advantages such as the 
ability to be easily engineered and synthesized, they bind or envelop therapeutic 
drugs, confer protection to the genetic therapeutic drugs, have virtually no 
immunogenic response, and given their differential release mechanisms and low cost 
(Zhang et al., 2004) these vehicles are an ideal partner for effective therapeutic gene 
delivery. Cationic liposomes are usually engineered such that they possess an amine 
polar head group region which facilitates the binding of negatively charged 
molecules, such as DNA. These liposomes have been shown to bind and complex 
with almost all of the DNA molecules in a given solution (Zhdanov et al., 2002) thus 
gaining much attention in gene delivery.  
 
Cationic liposomal formulations generally consist of a cationic lipid and, a neutral 




liposomes include, dimethylaminoethane carbamoyl cholesterol (DC-Chol), N-[1-
(2,3-dioleyoxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA), 
dioctadecylamidoglycylspermine (DOGS) and  dioleoyl trimethylammonium propane 
(DOTAP) (Figure 1.2). These lipids form the hydrophobic domain of the liposome 









Figure 1.2: Common cationic lipids that have been extensively used to engineer effectively 
competent liposomes.  
 
 
Lipids used for the formation of liposomes may contain up to three aliphatic chains. 
Previous research suggest that liposomes produced from a lipid containing one 
aliphatic chain form micelles and those formed from lipids containing three aliphatic 
chains transfect cells poorly (Karmali and Chaudhuri, 2007). Hence the hydrophobic 
domain of conventional liposomes usually contains two aliphatic linear chains and has 
shown to form transfection competent liposomes that possess a bilayer.  The linker 
bond forms a bridge between the polar head group and the hydrocarbon anchor. The 
linker group controls the degree of transfection since it governs the conformational 
flexibility, biodegradability and stability of the liposome. Commonly used linkers are 






Table 1.1: Various linker groups and advantages for their use in liposomal formulations 
(Adapted from Karmali and Chaudhuri, 2007).  
 






Esters DOTAP Biodegradable; Less Toxic Not chemically stable 
Disulfides DOPE Chemically stable; 
Biodegradable 
*None 
Ethers DOTMA Chemically stable Non-biodegradable 
Amides DOGS Chemically stable; 
Biodegradable 
*None 
 *No disadvantages documented thus far. 
 
 
Helper lipids that are generally used in the formation of liposomes include; 
dioleolyphosphatidylcholine (DOPC) and dioleoylphosphotidylethanolamine (DOPE). 
These are neutral lipids that impart no charge to the liposome, but are responsible in 
increasing the stability of the cationic liposome/DNA complex (lipoplexes) 
(Kawakami et al., 2008). Several studies have shown that liposomes engineered to 
contain DOPE in their formulation, yielded higher transfection efficiency (Zhang et 
al., 2010).  
 
When lipoplexes form, they exist as a lamellar packing of lipid and DNA. It is 
thought that DOPE, at a low pH, causes a conformational change in the packaging 
structure of the resulting lipoplexes. DOPE has been shown to convert this lamellar 
packaging into an inverted hexagonal packing structure. When in this conformation, 
the DNA is compacted further through electrostatic interactions (Chesnoy and Huang, 
2000) reducing premature loss of the DNA before reaching the aimed destination. The 
hexagonal conformation also allows for the efficient release of complexed DNA from 
the endosomal membrane (Zuhorn et al., 2005). In addition, DOPE has the ability to 
reduce the energy required for DNA binding by facilitating the release of ions from 











Tang and Hughes (1998) was the first to engineer a cationic lipid with a disulfide 
bond. The introduction of the disulfide linker was aimed to circumvent the poor 
release of the therapeutic DNA from the liposome into the cell cytoplasm. It has been 
shown that the incorporation of auxiliary lipids (such as DOPE and/or cholesterol) can 
render previously incompetent liposomes, competent (Mukherjee et al., 2005) and this 
characteristic enhances the  probability of researchers to utilize such a lipid in existing 
and novel formulations.  
 
 
1.2. THE USE OF POLYETHYLENE GLYCOL (PEG) 
 
Liposomes are nanoparticles that have gained much attention in gene delivery since 
they have the potential to penetrate through capillaries and reach target sites due to 
their small size. However when injected intravenously, liposomes are treated as 
foreign material by the host cell. Generally when liposomes are administered into a 
host, the host reticuloendothelial system (RES) recognises the material as foreign, 
resulting in the rapid elimination of the delivery vehicle. The surface of cationic 
liposomes is also known to attract plasma proteins which reduce the efficiency of the 
liposomes.  Liposomes were thus engineered to incorporate polyethylene glycol 
(PEG) in their formulation (Managit et al., 2005; Pathak et al., 2008). 
 
PEG is a neutral and synthetic polymer. This molecule is known to be soluble in water 
and in some organic solvents such as ethanol, methylene chloride, chloroform and 




linkage that acts as a hydrogen bond acceptor (Gad, 2007). The incorporation of PEG 
into liposomes yields an attractive liposomal formulation that is more resistant to 
degradation by serum nucleases in vivo. PEG is non-toxic to the cells, available in 
numerous molecular weights, easy to use and is readily excreted by the kidney, thus 
making it a desirable additive in liposomal generation (Metselaar et al., 2003).  
 
The U.S Food and Drug Administration (FDA) have approved the use of PEG in 
various applications including injectable pharmaceutical formulations, due to the non-
toxic properties of PEG.  In vivo studies have shown that when a PEGylated 
formulation is administered into the bloodstream it is rapidly expelled from the body.  
The clearance rate of PEG is considered to be inversely proportional to the molecular 
weight of the polymer, with PEG < 30 kDa being excreted via the kidney, and PEG 
molecules >20 kDa being excreted via the faeces (Gad, 2007). After its entry into the 
body, PEG is known to accumulate mainly in the liver, skin, muscle and bone.  It is 
important to note that the accumulation of the polymer is independent of molecular 
weight.  
 
The first research group to engineer PEGylated liposomes was Shimada and co-
workers (1997). They designed a liposome with PEG coupled to a glycoprotein. The 
liposome differed from the ‘norm’ since the galactose sugar incorporated in the 
liposome was separated from the lipid interface by the PEGylated chains at different 
lengths.  This particular system was engineered to evaluate the effect of the space of 
the PEG chains (PEG 10/20/40) and the anti-opsonic action of the PEGylated 
molecules. The main aim for varying spacer lengths was to improve the exposure of 
the ligand to its cognate receptor.  
 
PEGylated liposomes are frequently referred to as “stealth liposomes’ since they have 
been shown to increase the stability of the liposome, thus increasing the circulation 
time of the lipid structure, within the cell. Increase in stability is a result of the PEG 
molecules surrounding the surface of the liposome and forming a steric barrier which 
prevents (to a certain degree) the clearance of the lipoplexes by macrophages. The 
only disadvantage seen thus far with the use of PEG molecules is their lack of 
targeting to a specific organ. However it was also shown that the incorporation of 




endocytosis. Inhibition is dependent on both the percentage (in moles) of PEG 
molecules on the liposome and the type of functional group conjugated to the 
liposome (Shi et al., 2002).  
 
PEG can be incorporated into the liposomal bilayer (Moghimi et al., 2001) or 
activated and anchored into reactive phospholipids groups of previously formed 
liposomes. It has been demonstrated that the use of 3-7 mole % of PEG, increases the 
circulation time of the PEGylated particle, provided that the final size of the particle is 
within a size range of 70-200 nm. Circulation of the PEGylated liposome may also 
increase when phospholipids and cholesterol are added component to the formulation. 
The mechanism, by which the PEG increases the circulation of a given liposome, is 
governed by the ability of the PEG, to prevent binding of the liposome with opsonins 
in the blood. PEG molecules contain a “flexible” chain that has been shown to occupy 
the periliposomal layer (the space adjacent to the surface of the liposome) which 
shields the liposome. This enables the cationic liposome to escape recognition by the 
cell as foreign material. Thus the liposome is not rapidly removed by the Kupffer cells 
present in the liver (Immordino et al., 2006).  
 
With respect to the circulation half-lives of these stealth liposomes (PEGylated 
liposomes), it is estimated that in humans that liposomes remain in circulation in the 
blood for up to 45 hours following administration, and 15-24 hours in much smaller 
animals such as rodents.  The incorporation of PEG into liposomes is considered as a 
great stepping stone towards the perfect gene delivery vehicle for in vivo applications. 
PEG has been shown to be non-toxic to animals, and to shield cationic liposomes 
from proteolytic enzymes (Hinds and Kin, 2002). The PEGylated molecules provide 
the gene delivery vehicle with a camouflage that almost avoids recognition by the 
RES and prevents aggregation of the lipoplex thus prolonging circulation time (Gad, 
2007). PEG is capable of decreasing immunogenicity by blocking antibody sites. This 
in turn, increases solubility and allows for frequent dosing of the test formulation 
(Gad, 2007).   
 
There exist various types of PEG, with differences noted in the type of configuration, 
conformation, as well as in the molecular weight. With respect to the conformation, 




branched configuration is more efficient than a PEG molecule that bears a linear 
conformation (Chirino et al., 2004).  
 
 
1.3. NEW GENERATION OF LIPOSOMES: TARGETING TO A SPECIFIC 
ORGAN.  
 
There are two types of targeting that are associated with gene delivery; passive and 
active targeting (Figure 1.4). In passive targeting, genes or drugs are targeted to their 
specific target organ based on the physicochemical properties as well as the size of 
their carrier or themselves (in terms of the targeting of drugs to specific cells). 
Formulations already approved for human treatment, is the anthracycline drug, 
doxorubicin. Pharmaceutically this drug in its PEGylated form, is known as, Doxil, 
and is used to treat cancer in patients diagnosed with AIDS-related Kaposi sarcoma, 
as well as in patients with multiple myeloma. The drug offers lower cardiotoxicity 
whilst maintaining an increase in its efficacy when compared with treatment using 
free doxorubicin (Ning et al., 2007).  
 
Active targeting on the other hand employs the use of ligands that essentially will 
traffic the desired gene or drug to the specific target cell (Zhang et al., 2010).  This 
approach allows for a considerable amount of control in the targeting of genes to a 







Figure 1.4: Active and passive targeting to cells for drug targeting using liposomes. 
(Adapted from Ghosh et al., 2008). 
 
 
At regions of pathology where inflammation of the endothelium layer is predominant, 
different types of mediators (vascular endothelium growth factor and prostaglandins) 
have been shown to increase endothelial permeability. Underlying pathologies include 
cancer, rheumatoid arthritis and infection. Liposomes extravasate through the gaps 
between cells and enter the interstitial fluid (Ghosh et al., 2008). Active targeting is 
achieved by conjugating ligands to the liposome that bind to a specific target cell 
receptor, leading to internalization or release of the drug.  Table 1.2 provides some 
examples of active targeting. Passive targeting can be mediated by internalization or 












Table 1.2: Examples of active targeting drug delivery systems. aAGIP, amyloid 
growth inhibitory peptide; ASGP, asialoglycoprotein; mBAFF, mutant B cell 
activating factor belonging to the TNF family; SAP, sweet arrow peptide; TfR, 
transferrin receptor (Adapted from Malam et al., 2009). 
 
Ligand Receptor/ Target Study Findings 
Anti-CD74 
antibody, LL1  
CD74 receptor Ligand covalently attached to liposomes; selective for 




TfR Conjugation to the TfR-binding peptide significantly 
improves the anti-cancer potency and selectivity of the 
anti-cancer drug artemisinin 
Folate  Folate receptor 
(FR) 
FR is overexpressed on cancer cells 
Folate has been conjugated on liposomes loaded with 
doxorubicin for targeting of cancer and on NPs for targeted 
paclitaxel delivery 
mBAFF  BAFF receptor BAFF is the usual endogenous ligand for the BAFF 
receptor; mBAFF is a soluble BAFF mutant in which 
amino acids 217–224 are replaced by two glycine residues 
that can bind to BAFF receptors. PEGylated liposomes 
developed with mBAFF as a targeting ligand target certain 
B lymphoma cells in vitro. 
Hyaluronic acid  Hyaluronan 
receptors (HR) 
HT-29 cancer cells overexpress HR. Hyaluronic acid 
incorporated in chitosan NPs loaded with the anti-cancer 
drug 5-flurouracil exhibited higher cytotoxicity in vitro 
Galactose  ASGP receptors ASGP receptors are overexpressed on hepatoma cells. 
Dextran-based polymeric micelles were used to target liver 




With passive and active targeting, the delivery of transgenes and their subsequent 
expression is notably governed by the barriers that the delivery system encounters. 
Active targeting of genes is considered the most favourable choice in targeting since it 
has been observed to reduce serious adverse effects such as immune responses or 
cytotoxicity, and increase the transfection efficacy (Zhao et al., 2008).   
 
The delivery of genetic material to hepatocytes presents great potential to science and 
disease therapy since the hepatocytes are cells that play a key role in the synthesis of 




liver itself (Shigeta et al., 2007). Due to its relatively large size, the liver is a major 
site for lipid and protein production, allows accessibility to larger molecules, plays a 
role in metabolism, and is the site for the secretion of serum circulating polypeptides 
and numerous enzymes. The organ is also described as being partially “immuno-
priviledged” since it bares tolerance to immunological reactions that occur when 
foreign material escapes the gastrointestinal tract and gains entry into the liver via the 
portal system (Pathak et al., 2008).  
 
The liver is an organ consisting of different cell types. These include the highly 
important liver parenchymal cells (hepatocytes), liver macrophages (kupffer cells) and 
the sinusoidal endothelial cells. Hepatocytes make up 80 % of the total mass of the 
liver and hence serve as a potential target for gene delivery aimed at treating various 
liver associated diseases, such as Hereditary Hemochromatosis, Wilson’s disease and 
Hepatocellular Carcinoma (HCC) (Pathak et al., 2008).  
 
Nanomedicine is a promising approach to clinical practice, providing resolution to 
crucial limitations faced by the diagnoses, treatment and maintenance of human 
diseases. The various branches of nanomedicine include drug delivery (Yokoyama 
2005), regeneration of tissues (Zhang and Webster, 2009) as well as imaging using 
Quantum dots (Jamieson et al., 2007). The use of liposomes as delivery vehicles is 
regarded as a ‘mainstream’ gene or drug delivery technology. Various ligands have 
been engineered for their bio-sensing and bio-signalling to liver hepatocytes. 
Hepatocytes express the asialoglycoprotein receptor (ASGP-R) on their sinusoidal 
surface. These receptors recognize and specifically bind asialoglycoproteins or 
galactosylated polymers and internalize these molecules. From all ligands researched 
for gene delivery, the galactose moiety has proven to be the ligand with the greatest 
potential for targeting to hepatocytes. Numerous attempts have been made by 
researchers, to use galactosylated liposomes to target liver parenchymal cells, both in 
vitro and in vivo (Kawakami et al., 2000, Kawakami et al., 2002, Higuchi et al., 








1.3.1. The Asialoglycoprotein Receptor (ASGP-R)  
 
Present on the surface of mammalian hepatocytes are the asialoglycoprotein receptors. 
These receptors are abundantly expressed on the surface of the liver parenchymal 
cells and thus have gained much interest in gene therapy. Besides being expressed in 
abundance, the ASGP-R contains approximately 1 - 5 x 105 binding sites/cell. The 
ASGP-R is randomly dispersed throughout the basolateral sinusoidal plasma 
membrane domain, in the direction facing the capillaries. Furthermore the receptors 
are thought to be found in either uncoated or coated pits and usually located with 
mannose-6-phosphate, poly-(Ig) and transferrin receptors (Pathak et al., 2008).  
 
The morphology of the blood capillaries varies between different organs, with the 
liver containing discontinuous capillaries that exhibit inter-endothelial junctions with 
a large diameter of up to 150 nm. Thus the size of the DNA/cationic liposome 
complex should ideally be less than 150 nm in size, in order for the lipoplexes to 
bypass the capillaries (Takakura et al., 1998). The receptors recognize their specific 
substrates, which are glycoproteins that bear either a terminal galactose or an N-acetyl 
glucosamine. The proteins are internalized via clathrin coated pits and transported to 
the intracellular compartments. This natural process is adapted such that synthetic 
substances may be coupled with a desired ligand (lactose or galactose) and 
internalized into the cell by a process termed receptor-mediated endocytosis (RME).  
The attachment of a lactosylated or galactosylated moiety to the surface of a liposome 
was found to increase the uptake of the liposomal formulation by the liver cells (Wu 





The success of a delivery vehicle to efficiently deliver nucleic acids to a specific site 
is dependent on the ability of the vehicle to firstly enter the cell; bypass digestion by 
serum nucleases, and to gain access to a specific target organ in an appropriate 
concentration. Generally, the nucleic acid adheres to a cell surface protein and is 
internalized into the cell. The nucleic acids are then released into the cell and are 




Chaudhuri, 2007). The electrostatic repulsion that exists between naked DNA 
(negatively charged) and the phosphatidyl bilayer (negatively charged) lowers the 
possibility for the diffusion of the naked DNA into the cell, to occur. DNA may enter 










The endolytic pathway is subdivided into two classes, pinocytosis (phenomenon 
called cell drinking) and phagocytosis (phenomenon called cell eating). The process 
of endocytosis involves several steps. It is believed that the spontaneous engulfment 
of DNA initiates the start of the endolytic pathway. This is followed by invagination 
of the plasma membrane (inward folding of the membrane) which results in the 
formation of a droplet of the extracellular membrane. The droplet is fully formed once 
it pinches off from the cell membrane which yields an endosome (an intracellular 
coated vesicle which envelopes the ingested material DNA). These endosomal 




endosomes. Endosomes may fuse with primary lysosomes that contain numerous 
hydrolytic enzymes resulting in the formation of a secondary lysosome. Due to the 
large content of hydrolytic enzymes in the lysosome, the formation of the secondary 
lysosome, results in the termination of the gene delivery process since the DNA is 
degraded by the enzymes. The endocytic membrane is re-cycled as it is known to 
return to the plasma membrane. It is only when a delivery vehicle can bypass the 
lysosomes, that the DNA can transverse the cytoplasm and reach the nucleus (Pathak 
et al., 2008; Elouahabi and Ruysschaert, 2005).  
 
Cationic liposomes face numerous barriers with the most potent barrier, in vivo, being 
digestion of the therapeutic DNA by serum nucleases present in the blood (Yang and 
Huang, 1997). The anionic proteins present in the serum are thought to have an 
inhibitory effect on transfection (Audouy et al., 2000). Once the lipoplex enters the 
cell, the negatively charged serum proteins are attracted to the cationic liposome/DNA 
complex and attach to the complex. This results in the aggregation of lipoplex which 
either precipitates out the complex or causes the complex to disintegrate, thus 
releasing the corrective DNA well before it can reach its target site. Hence serum 
proteins have led to the reduction or inefficiency of corrective DNA delivery (Li et 
al., 2011).  
 
Numerous strategies have been developed to overcome this barrier. These include the 
manipulation of existing liposomal formulations such as the amino acids and alkaline 
cationic lipids (Obata et al., 2008) and the addition of helper lipids such as PEGylated 
lipids (Ross and Hui, 1999). An increase in the positive charge ratio of the cationic 
liposome/DNA complex (1.0-4.0) has also shown increased transfection in 20% 
serum (Yang and Huang, 1997). However in the case of excessive positive charge, the 
cationic liposome is directed almost exclusively to the lung. Hence targeting to 
another organ, such as the liver, would render this approach unfavourable (Kawakami 
et al., 2008). Li and co-workers (2011) have shown that the fate of lipoplexes in vivo 
is dependent on three crucial aspects: the headgroup of the liposome, the stability if 
the lipoplex and the degree of cellular uptake. An increase in the lipid content during 




1.4. RECEPTOR MEDIATED ENDOCYTOSIS AND THE FATE OF 
LIPOSOMES IN VIVO 
 
In vivo studies often face barriers that dampen their effective delivery to the target 
cell. These include enzymatic degradation of the nucleic acids in the blood; the 
lipoplex interaction with the blood components causing aggregation (mentioned 
above), as well as the non-specific uptake of the lipoplex by other cells (Kawakami et 
al., 2008). It has been shown that the administration of naked therapeutic DNA 
(intravenous route) induces virtually no gene expression (Kawabata et al., 1995). 
Hence advances have been made regarding a carrier system for the plasmid DNA.   
 
Since the first successful in vivo transgene expression which was reported by Zhu et 
al (1993) using the DOTMA/DOPE system, considerable strides have been made in 
gene delivery. Cationic liposomes possess the ability to condense DNA which helps 
prevent the premature detachment of the corrective DNA prior to the DNA reaching 
its target cell, allowing for a greater amount of the corrective DNA reaching the target 
cell. Intravenous injection of traditional lipoplexes, have shown to accumulate 
predominantly in the lung since the lungs are the first to trap these complexes, 
creating a problem when the target organ is not the lung. 
 
Many researchers have shown that target organ specificity may be achieved via 
receptor mediated endocytosis. Liposomes can be grafted such that the polar head 
group region bears a ligand that is specific for a receptor that is located, in abundance, 
on the target cell. For example, liver cells overexpressing the asialoglycoprotein 
receptor (ASGP-R) are specific for the sugar galactose. Hence tagging a cationic 
liposome with galactose moiety would essentially target the liposome to hepatocytes, 







Figure 1.6: The generation of a cationic liposome grafted such that it possesses a 
ligand (galactose) that binds to the ASGP receptor present on the surface of 




Galactosylated cationic liposomes, such as Gal-C4-Chol (Kawakami et al., 2000; 
Fumoto et al., 2003) showed successful in vivo gene delivery specifically to 
hepatocytes. The ability to travel through the vascular walls of the cell presents a 
problem for delivery vehicles. In the liver, the sinusoidal wall does not possess a 
basement membrane but contains a fenestrated endothelium which is approximately 
100-150 nm in diameter. Thus for efficient gene delivery to hepatocytes, the delivery 
vehicle should ultimately be smaller than 100-150 nm in size to travel through the 
fenestrae and gain access to the space of Disse (or perisinusoidal space) which lead 
directly to the target hepatocytes (Pathak et al., 2008). The studies of Shimada and co-
workers (1997), using Gal-PEG10-lip showed that when the liposome was 
administered in vivo, the formulation was rapidly cleared from the system with a half- 
life (t1/2) of 30 minutes. They compared this with a control (liposome without Gal-
PEG-10-lip) and established that the control liposome had a half-life (t1/2) of 12 hours.  
The group further showed that the rapid clearance was due to an enhanced uptake of 
the Gal-PEG-10-lip liposome (>90 % of the dose administered) by kupffer cells 




the spleen was only 1 % of the total volume injected into the animal. Interestingly, 
injecting Gal-PEG-Lip liposomes following the administration of N-
acetylgalactosamine, showed a reduction in the rate of clearance compared to the 
control levels (initial rate of plasma clearance). The group also investigated the effect 
of PEG-DSPE (monomethoxypoly(ethyleneglycol)) incorporated into the Gal-PEG10-
Lip and found that the PEG-DSPE only partially reversed the rate of plasma clearance 
of the liposome in the liver and  spleen. They concluded that Gal-liposomes are 
recognized by the kupffer cells and removed from the cell.  
 
Murao and co-workers (2002), evaluated the targeting efficiency of galactosylated 
liposomes to hepatocytes, based on a varying amount of lipid. The group synthesized 
various liposomal formulations, which consisted of 1,2-distearoyl-sn-glycero-3-
phosphocholine (DSPC), cholesterol (CHOL), and cholesten-5-yloxy-N-(4((1-imino-
2-D-thiogalactosylethyl)amino)butyl)formamide. The liposomal formulations were 
analysed in vivo, through intravenous injection to mice. They proved that liposomal 
formulations containing galactose were solely taken up by the liver hepatocytes, 
whereas those formulations without the galactose sugar were found to be distributed 
amongst the hepatocytes and nonparenchymal cells. However, when the molar ratio of 
DSPC was increased (to 90 %), in both the liposomal formulations, the uptake of the 
liposomes into the nonparenchymal cells increased dramatically. Since the results 
were constant for liposomes containing and those lacking the sugar moiety, it is 
possible that the uptake and internalization of the liposomes were based on a 
mechanism other than internalisation by the asialoglycoprotein receptor.    
 
As mentioned previously, the major limitation of the use of cationic liposomes in gene 
delivery is the poor targeting potential. Liposomes have to be targeted to their specific 
target organ. Once the lipoplex is inside the cell, efficient endosomal release of the 
pDNA into the cell cytosol is crucial. Once released, the DNA is further subjected to 
cytosolic nucleases that may degrade existing DNA. Trafficking of adequate DNA 
into the nucleus is important since the DNA must gain access to the transcriptional 
machinery (Karmali and Chaudhuri, 2007). Targeted gene delivery was one of the 
most crucial barriers that have now been overcome using cationic liposomes. 




be within a specific size range due to the structural differences of the blood capillary 
walls in various tissues and organs.    
 
An ideal nanosystem ensures that the lipoplex arrives and acts only on the selected 
targeted cells. The carrier must be biocompatible and biodegradable. This means that 
the liposome, which forms part of the lipoplex, should, upon entering the cell, 
metabolize or degrade into non-toxic components. Furthermore, these components 
should be rapidly expelled from the cell upon degradation.  
 
 
1.5. HYPOTHESIS  
 
RME allows for the site specific delivery of foreign genes via receptors. Various 
ligands have been used to target the receptors present on the surface of the 
hepatocytes (asialofeutin, asialoorosomucoid, lac-BSA, asialolactoferrin, 
asialoceruloplasmin, and galactose). However the ligand showing the greatest interest 
for gene delivery thus far (both in vitro and in vivo), is the galactose moiety. Thus 
three different galactosylated cationic liposomal formulations were subjected to in 
vitro analyses in an attempt to compare the three formulations, to determine, which 
formulation yields the best transfection efficiency. The best liposomal formulation in 
vitro will determine the direction in which future studies need to be focussed, in order 
to produce a viable gene delivery vector for clinical studies.        
 
 
1.6. OUTLINE OF THESIS  
 
In this project, a comparative study of three distinct, galactosylated cationic liposomal 
formulations in gene delivery was carried out. The three galactosylated liposomal 
formulations in this study were targeted specifically to the liver hepatocytes via the 
ASGP-R to establish which of the three liposomes was the most efficient in 
hepatocyte transfection. Of the three liposomes being tested, two were synthesized 
and analysed at the UKZN-Westville, Biochemistry department and the other at the 
Chemistry department, University of the Witwatersrand. All three liposomes were 




under similar conditions despite exhibiting high transfection activities in vitro 
(Narainpersad et al., 2012; Singh et al., 2007).  
 
Both PEGylated and non PEGylated galactosylated cationic liposomes were 
investigated, in vitro, for cytotoxicity and luciferase gene expression, in the human 
hepatocellular carcinoma cell line, HepG2, and the human embryonic kidney cell line, 
HEK293 (control ASGP-R negative cell line). The three unique galactose targeted 
liposomes are: Cholesteryl-3β-N – (4-aminophenyl-β-D-galactopyranosyl) carbamate; 
Cholest-5-en-3-yl [1-(β-D-galactopyranosyl)-1H-1,2,3-triazol-4-yl]-methylcarbamate; 
Cholesteryl-β-D-galactopyranoside. Untargeted, PEGylated and non PEGylated 
liposomes were also be prepared and investigated for comparison. All cationic lipids 
were analysed by NMR, and liposomes and lipoplexes were characterised by electron 
microscopy. Liposome:DNA interactions were characterised by band shift and 






















2.1. INTRODUCTION  
 
Liposomes are formed when amphiphilic molecules, are exposed to an aqueous 
environment. This is a spontaneous reaction in which the hydrophilic molecules 
protect the hydrophobic molecules, from the aqueous layer (Karmali and Chaudhuri, 
2007).  
 
Liposomes have the ability to entrap drugs within their aqueous core or to bind them 
on the surface of their structure. The process is greatly dependent on the method used 
to synthesize these nano-sized vesicles. Often when liposomes are prepared, 
conditions are metastable. This means that the state of free enthalpy and the 
environment in which the liposome are synthesized are not in equilibrium. Liposomes 
synthesized in a metastable state, have the capability to change their morphological 
conformation producing a heterogeneous mixture of size, lamellarity, and shape, with 
time (Lautenschlager, 2006). A variety of techniques have been employed for the 
preparation of liposomes. These include extrusion of lipid suspensions through filters, 
ethanol injection, detergent depletion, ether injection, thin lipid film hydration and 
reverse phase evaporation (Lasic, 1997; Campbell, 1995; Torchilin, 2003; Deamer 
and Bangham, 1976; Gao and Huang, 1991; Szoka and Papahadjopoulos, 1978). 
 
Lipid amphiphiles are chemically designed to embody three unique structural 
domains; the hydrophobic anchor, the linker and/or spacer element and the 
hydrophilic headgroup (Figure 2.1). The nature of the cationic lipid used as the 
hydrophobic anchor, can either consist of a fused ring system such as that seen in 
steroids (cholesterol) or lipids containing long hydrocarbon chains engineered in the 










Figure 2.1: Segments of a typically formulated cationic liposome. 
 





DC-Chol was the first steroid-based lipid to be used in liposomal formulations and to 
date is the most commonly utilized cationic lipid. It has been shown that this 
particular steroid-based lipid confers lower toxicity and greater transfection 
efficiency. Cationic cholesterol lipids proved superior over previously used glycerol-
based amphipiles (Biswas et al., 2009). The major advantage of using cholesterol is 
that the 3β-OH of the lipid accommodates for structural modification at the linker 
element and hydrophilic head group.  
 
The linker element attaches the cholesteryl moiety to the cationic head group. 
Commonly used linker elements are esters, ethers and amides. The linker group 
governs the biodegradability, chemical stability and transfection efficiency of the 
cationic lipid. The linker bridge is sensitive to numerous biological stimuli within the 
cell. This sensitivity allows for the release of DNA from the lipoplex (liposome:DNA 
complex) at specifically defined end points (Biswas et al., 2009). Helper lipids 
generally form a component of the cationic liposomal formulation. Co-lipids such as 
DOPE, cholesterol and DOPC assist in low cell toxicity and effective gene transfer 
(Mukherjee et al., 2005). The positively charged hydrophilic head group allows for 
the interaction and optimal binding of the negatively charged corrective DNA. During 
the spontaneous formation of the lipoplex, the cationic lipid acts as a catalyst and aids 
in the binding of the DNA to the liposome and its subsequent compaction. An 
imperative property of the amphiphile is its geometry. When suspended in an aqueous 
environment, the cationic lipids can adopt various structural phases. These phases 
include the lamellar, cubic, micellar and inverted hexagonal phase (Wasungu and 









This chapter describes and discusses the preparation and characterization of eight 
unique cationic liposomes. All contain the cationic cholesterol derivative, N,N-
dimethylaminopropylamido- succinylcholesterylformylhydrazide (MSO9) and the 
neutral co-lipid dioleoylphosphatidylethanolamine (DOPE). The three targeted 
liposomes have been strategically formulated to incorporate a galacto glycolipid (10 
mole %). Liposomes were prepared with and without 
dioleolphosphatidylethanolamine-polyethylenegylcol2000 (DOPE-PEG2000) at  2 mole 
%.   
 
 




Dioleoylphosphatidylethanolamine was purchased from the Sigma Chemical 
Company, St Louis, MS, USA. Silca gel 60 F254 chromatography plates and the 2-[4-
(2-hydroxyethyl)-1-piperazinyl] ethanesulphonic acid (HEPES) were purchased from 
Merck, (Damstadt, Germany). Dioleoylphosphatidylethanolamine polyethylene 
glycol2000 (DOPE-PEG2000) was purchased from Avanti Polar Lipids, Alabaster, USA. 
MS04 was synthesised previously in the Biochemistry laboratory. All other chemicals 





2.2.2.1. Synthesis of the cholesterol derivative, N,N-
dimethylaminopropylamidosuccinylcholesterylformylhydrazide (MSO9) from 
Cholesterylformylhydrazide (MSO4)  
 
MSO4 (223 mg, 0.5 mmole) was treated with succinic anhydride (55 mg, 0.5 mmole) 
in dimethylformamide:pyridine (5 ml), and incubated at room temperature overnight. 
The solvent was then removed using a rotary evaporator, under reduced pressure. 
Thereafter, absolute ethanol was added to the flask, yielding the product, 
cholesterylformylhydrazide hemisuccinate (MSO8) as white crystals. The yield of the 




140 mg dicyclohexylcarbodiimide (DCC, 0.68 mmol) and 78 mg N-
hydroxysuccinimide (0.68 mmol) were dissolved in 3 ml of DMF. This was then 
warmed at ± 50 oC. The reaction was monitored by TLC, using a silca gel 60F254 TLC 
plate in 9:1 (v/v) choloform:methanol. The reaction was allowed to proceed overnight 
whereupon dicyclohexylurea crystals formed. The crystals were then removed by 
filtration, followed by evaporations of the filtrate under vacuum. Chloroform was then 
added to the product followed by water to extract any excess N-hydroxysuccinimide. 
The chloroform layer was then evaporated, and petroleum ether was thereafter added 









2.2.2.2. Cholesterol 3β-N-(4-aminophenyl-β-D-galactopyranosyl) carbamate 
 
The synthesis of, cholesterol 3β-N-(4-aminophenyl-β-D-galactopyranosyl) carbamate 
was adapted from Narainpersad et al., (2012). Cholesteryl chloroformate (33 mg, 74 
µmoles) and 4-aminophenyl-β-D-galactopyranoside (p-NH2-Ø-Gal) (20 mg, 74 
µmoles) were dissolved in DMF (2 ml). Thereafter triethylamine (10 µl) was added 
and the reaction mixture was set aside at room temperature overnight. Completion of 
the reaction was confirmed by TLC as described below.  
 
The reaction mixture was tested against the starting galactoside, p-NH2-Ø-Gal, on 
silica gel 60 F254 plates, in a chloroform:methanol (4:1 
v/v) solvent system. DMF, the 
solvent component of the reaction product, was evaporated via rotary evaporation 
using a Buchii Rotavapor-R. Water was added to the residue to extract any remaining 
unreacted starting galactoside. The mixture was incubated at 4 oC for 2 hours and the 
crude product isolated by filtration. This was extracted further with ether (overnight) 
and the product was finally isolated by centrifugation in a MSE bench top centrifuge 












































































Figure 2.4: Schematic representation of the synthesis of WT. The conjugation of the 












2.2.2.4. Preparation of Cationic Liposomal Formulations 
 
All of the eight cationic liposome formulations (both PEGylated and non PEGylated) 
were prepared by the method of Gao and Huang (1991). The specific quantities of 
each component of each liposome are as follows:  
 
 














Control 1 2 2 - - 
Control 2 2 1.8 - 0.2 
MS 1 2 1.6 0.4 - 
MS 2 2 1.4 0.4 0.2 
NN 1 2 1.6 0.4 - 
NN 2 2 1.4 0.4 0.2 
WT 1 2 1.6 0.4 - 
WT 2 2 1.4 0.4 0.2 
 
Non-PEGylated                                                                                           PEGylated 
Control 1= Untargeted                                                                                 Control 2= Untargeted  
MS1= Cholesteryl-β-D-Galactopyranoside                                                  MS2= Cholesteryl-β-D-Galactopyranoside 
NN1= Cholesteryl-3β-N-(4-aminophenyl-β-D-                                                         NN2= Cholesteryl-3β-N-(4-aminophenyl-β-D-  
             galactopyranosyl) carbamate                                                                                      galactopyranosyl) carbamate 
WT1= Cholest-5-en-3-yl [1-(β-D-galactopyranosyl)-                                               WT2= Cholest-5-en-3-yl [1-(β-D-galactopyranosyl)- 




The appropriate reagents were dissolved in 1 ml dry chloroform. The chloroform was 
evaporated and the sample was deposited on the inner wall of the test tube by rotary 
evaporation, in vacuo at 21 oC, using a Büchii Rotavapor-R. Thereafter the sample 
was subjected to a further drying step in a drying pistol for approximately 1.5 hours. 




rehydrate the sample. The samples were incubated overnight at 4 oC, and thereafter, 
vortexed and sonicated for 5 minutes on a Transonic bath-type sonicator to generate 
unilamellar liposomes. Samples were then stored at 4 oC. Thereafter all liposomal 
formulations were vortexed for 30 seconds and sonicated for 30 seconds, prior to use 
and storage.   
 
All formulations (excluding C1 and C2) contained a constant molar quantity of the 
galacto component (10 mole %). PEGylated liposomes contained DSPE-PEG2000 (2 
mole %).  
 
 
2.2.2.5. Nuclear Magnetic Resonance (NMR) Spectrometry 
 
Samples of the cholesteryl galacto derivatives (4 mg) were dissolved in 
deuteropyridine (C5P5N) and subjected to 
1H and 13C NMR one dimensional analysis 




2.2.2.6. Characterization by Transmission Electron Microscopy (TEM) 
 
For TEM, liposome suspensions were diluted 1:4 in HEPES Buffer Solution (HBS). 
Approximately 1 µl of the diluted liposomal formulation was pipetted onto a carbon 
coated copper grid. This was followed by the addition of 1 µl of uranyl acetate 
(saturated) which was smeared across the grid using the tip of the pipette. After 2-3 
minutes the excess liquid was removed using filter paper.  The grid was thereafter 
quickly dipped into liquid nitrogen using a spring loaded Leica CPC system. The 
grids were transferred to a Gatan cryotransfer system. An appropriate amount of 
liquid nitrogen was poured over the grid to cover it and cool the system. The grids 









2.3. RESULTS AND DISCUSSION  
 
2.3.1. Synthesis of the Cholesteryl Derivative, MSO9 
 
The synthesis of MS09 was followed using Thin Layer Chromatography (TLC) on 
silica 60F254 plates developed in CHCl3:MeOH (4:1 
v/v). The schematic 
representations of the TCL plates are shown below. 
 
        










Figure 2.5: TLC representing two crucial steps of MS09 synthesis. (a) Products of the 





The animal cell membrane is constituted largely by the lipid cholesterol and due to its 
biocompatibility, the lipid has been frequently employed as the hydrophobic segment 
of cationic cytofectin. The use of cholesterol and cholesterol derivatives, as additive 
to conventional liposomal formulations, have been shown to rapidly reduce the 
release of bioactive compounds that is encapsulated (Tran et al., 2009). Cholesterol is 
composed of a hydroxyl group (polar) and a steroidal ring system (non-polar), with an 
isopentyl chain. Embedded within the liposomal bilayer of cationic liposomes are 
apolar cholesteryl skeletons which represent the hydrophobic anchors of the liposome. 


















Reynier et al., 2004), which may be an amide (Hasegawa et al., 2002), ether (Ghosh 
et al., 2000), ester (Lee et al., 2004) or carbamoyl entity (Gao and Huang, 1991).  
 
The synthesis of the cholesterol derivative, MS09 was successfully achieved in 4 
steps (Figure 2.2). The first step involving addition of previously synthesized MS04, 
succinic anhydride. As shown in Figure 2.5 (a), the product yielded was MS08. 
However, the reaction mixture contained a small proportion of unreacted MS04.  
MS04 displays an amino functionality that is succinylated in the formation of MS08. 
The hydrazide product MS04 is relatively non-polar and displays a high Rf value in 
CHCl:MeOH (4:1 v/v).  
 
The next step involved the coupling of the N,N-dimethylaminopropylamine and 
hemisuccinate (MS08) to form a chemically stable amide linkage. This was achieved 
by N-hydroxysuccinimide activation of the MS08 carboxyl group. The TLC plate in 
Figure 2.5 (b) shows the three components in the final step of the synthesis. The 
desired product, MS09 was synthesized in high yield, with only a small fraction of the 
starting compound MS04 in the reaction mixture.  
 
As mentioned before the cationic cholesteryl derivative synthesized in this study has 
the classic structure of a cytofectin, with a cationic head group, spacer arm (of varying 
lengths), linker bond and the hydrophobic lipid anchor. MSO9 is a cholesterol 
derivative that has been shown to be effective and efficient in attaining sustainable 
transfection efficiency in different cell lines (Singh and Ariatti, 2006). The lipid 
boasts a dimethylamino cationic head group, attached to a fused ring system.  This 
cationic lipid has been synthesized previously by Singh and Ariatti (2006) and has 
promoted remarkably high transgene expression, in the HepG2 cell line. The lipid 
showed minimal toxicity to the cell lines, and it is due to this characteristic, that 








2.3.2. Synthesis of Cholesteryl Derived Ligand [Cholesteryl-3β-N-(4-
aminophenyl-β-D-galactopyranosyl) carbamate] 
The product was synthesized as outlined in section 2.2.2.2, and completion of the 
reaction was confirmed visually using TLC.  
 
 
     








Figure 2.6: Thin Layer Chromatography of cholesteryl-3β-N-(4-aminophenyl-β-D-
galactopyranosyl) carbamate in a 4:1 (v/v) chloroform:methanol (Standard = p-NH2-ø-




Cholesteryl-3β-N-(4-aminophenyl-β-D-galactopyranosyl) carbamate (NN) was 
synthesized from cholesteryl chloroformate and p-aminophenyl-β-D-
galactopyranoside. The product was visualised against the standard p-NH2-ø-Gal 
(Figure 2.6). The synthesis of NN, resulted in a high yield of the product in pure form. 
The TLC plate was sprayed with 10 % (v/v) sulphuric acid to dehydrate the reaction 



















2.3.3. Preparation of Cationic Liposomes 
 
All liposomes were prepared in accordance with Table 2.2 above. Figures 2.7-2.9 



























Spacer length = 9.945 Å Molecular mass = 
683.91424 
Chemical formula = 
C40H61NO8 
 















Spacer length = 10.007 Å Molecular mass = 
672.8949 












Spacer length = 2.42 Å Molecular mass = 
548.79414 















Cationic liposomal formulations were prepared from near equimolar ratios of MS09 
and DOPE.  The two crucial factors that govern the linkage element, that adjoins the 
anchor to the targeting moiety, are the chemistry and length of the linker element. 
These two factors accommodate the cohesive charge–charge interactions in lipoplexes 
thus influencing their resulting degree of transfection obtained (Singh and Ariatti, 
2006 and Reynier et al., 2004). Figures 2.7-2.9 exhibit the chemical structure and 
formula of each galacto derivative, together with the measured spacer length. Cholest-
5-en-3-yl [1-(β-D-galactopyranosyl)-1H-1,2,3-triazol-4- yl]methylcarbamate  displays 
the greatest spacer length (10.007 Å)  between the galactose sugar and the cholesterol 
derivative. This is marginally greater than that in cholesteryl-3β-N-(4-aminophenyl-β-
D-galactopyranosyl) carbamate (Figure 2.7), with a spacer length of 9.945 Å. The 
greatest difference evaluated was the spacer length of cholesteryl-β-D-
galactopyranoside (2.42 Å). Singh and Ariatti (2006) demonstrated the vast increase 
in transgene expression with the use of a longer spacer.  
 
When liposomes are engineered to contain equimolar quantities of DOPE and the 
cationic lipid, higher transfection efficiency in vitro can be achieved compared to the 
use of a different helper lipid such as DOPC. We can attribute this to the unique 
ability of DOPE, to transition the bilayer into an inverted hexagonal configuration, 
under specific conditions, such as acidic pH. This transition facilitates endosomal 
membrane destabilization and subsequent release of the liposome. In vivo studies have 
shown that the inclusion of cholesterol, instead of DOPE, as a co-lipid significantly 
increased transgene expression, since lipoplexes formed demonstrated vastly 













2.3.4. Characterization of liposomes and lipoplexes by TEM   
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Figure 2.10: Ultrastructure images of (A) untargeted cationic liposomes, C1 and (B), 





































Figure 2.11: The morphology of targeted cationic liposomes and the PEGylated 
counterparts (A) MS1 (B) MS2 (C) NN1 (D) NN2 (E) WT1 (F) WT2. Bar = 100 nm 
except in A (Bar =200 nm). 
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The morphology of the liposomes was analysed using TEM. There are many tools and 
techniques that have been developed to determine particle size distribution. There are 
many techniques that have been developed to determine particle size and distribution. 
These include the zeta potential and TEM. However, visual characterization of 
liposomes is considered the most important technique (LeDoux, 2008). By visualizing 
a sample by electron microscopy, the true size distribution and shapes of the liposome 
can be determined (Betageri et al., 1993; Frederik et al., 1996). 
 
Liposomes were prepared from the cytofectin MSO9 and DOPE at near equimolar 
ratios, at a concentration of 4 µmol lipid per millilitre of HBS. From the diluted 
samples, visualized by TEM (Figure 2.10-2.11) it can clearly be concluded that all 
liposomal formulations, consisted of unilamellar liposomes. Unilamellar liposomes 
can be formed when multilamellar liposomes are sonicated. Small unilamellar 
liposomes range between 10-100 nm in size while the large unilamellar liposomes 
range between 150-250 nm (Karmali and Chaudhuri, 2007). These can be stable at 4 
oC for several months. Multivalent cationic lipids have a probability of forming 
micelles which yield unstable liposomes. All TEM ultrastructures obtained show that 
the liposomal formulations yielded liposomes that were unilamellar and mostly 
spherical in shape (Figure 2.9 A-H). The estimated size range for the unilamellar 













PREPARATION AND CHARACTERIZATION OF 
GALACTOSYLATED CATIONIC LIPOSOME – DNA 






Liposome:DNA complexes are self-assembled nanosystems that form as a result of 
electrostatic interactions that occur between the positively charged lipid and the 
anionic DNA (Felgner et al., 1997). The formation of the cationic liposome:DNA 
complexes, occurs in two unique steps. The first step is an endothermic process 
involving the rapid attraction and subsequent binding, between the DNA and the 
liposomal surface. The second step is a gradual endothermic reaction that has been 
suggested to be involved in the fusion of the two entities and the resulting structural 
rearrangements (Zhdanov et al., 2002). During lipoplex formation, the electrostatic 
interactions that occur between the cationic lipid and the anionic DNA, results in the 
collapse of the DNA structure, a process known as condensation.  The DNA is tightly 
compacted or condensed to the lipid which allows the lipid to shield and protect the 
DNA from nucleases (Wasungu and Hoekstra, 2006).  
 
During the preparation of lipoplexes, the order in which the liposome preparation and 
DNA solution are introduced to each other is crucial. When the negatively charged 
plasmid DNA is added to a specific volume of liposome, the resulting lipoplex formed 
will exhibit a gradual increase in size. However, when the cationic lipid is added to 
the plasmid DNA, the lipoplexes generated following incubation, are roughly similar 
in size and the preparations seem more stable. The lipoplexes continue to form until 
the cationic lipid (positive charge) exceeds the nucleic acids (negative charge) 
available in solution (Kennedy et al., 2000). The morphology of the lipoplex, size of 
the lipoplex, the ratio of cationic lipid to nucleic acid and liposome composition 
govern the transfection efficiency that can be achieved in a cell line (Boffi et al., 
2002; Obata et al., 2008).  Positively charged liposomes that complex with DNA, 




composition. Many morphological structures have been reported, which include the 
commonly seen string of beads (Gershon et al., 1993), spaghetti and meat ball, 
inverted hexagonal phase, sliding columnar phase, map-pin and the multilamellar 
structures (Ma et al., 2007). Various factors that affect the success of the liposomal 
formulations and their resulting gene transfer efficiency are outlined below in Table 
3.1. The nature of the initial lipid, size of the plasmid DNA, and the inclusion of 
helper co-lipids such as DOPE, modulate lipoplex stability and transfection efficiency 
(Wasungu and Hoekstra, 2006). In the present study we have taken all of the below 
mentioned factors listed below into consideration, prior to the initiation of liposomal 
preparations.  
 
Table 3.1: Factors governing the biological activity of lipoplexes, in vitro and in vivo 
(Simões et al., 2005).  
 
Related Properties  Affecting Factors 
Mode of lipoplex formation 
- morphology and structure 
 
Nature of cationic and helper lipid, stoichiometry of cationic lipid 
and DNA, nature of the medium (ionic strength, pH and 
temperature), DNA structure 
Control of physicochemical 
properties 
- size 
- net charge 
 
Mode of lipoplex preparation (type of liposomes, DNA structure, 
order of addition and rate of mixing, lipid and DNA 
concentration), role of adjuvants (polycations, surfactants, 
cryoprotectants) 
In vitro and in vivo 
performance 
- stability in the presence of 
serum 
- resistance to DNA nuclease  
  degradation 
-pharmacokinetics/ 
biodistribution 
-passive versus active targeting 





Route of administration, nonspecific interaction with serum 
components, interaction with blood cells, net charge of the 
lipoplexes, nature of the colipid (cholesterol versus DOPE) 
 
Interaction with serum components, opsonisation, prolonged 
circulation time (inclusion of poly[ethyleneglycol]) 
Size, use of ligands and antibodies 
Unknown 
Level and duration of gene expression 
Type and concentration of lipid, type of cell 
Lipoplex–cell interaction 
- mode of cellular 
internalisation 
-escape from endosomes 
-DNA dissociation from the 
complex 
-trafficking of DNA into the 
nucleus 
 
Size, liposome composition, net charge and topology of the 
complexes, presence of ligands 
Nature of helper lipid, use of endosome disrupting agents 
Net charge of the complex, nature and valency of the cationic 
lipid. Cellular factors unknown 
Degree of DNA condensation/compaction, protection from 




In 1998, using x-ray diffraction, Koltover and co-workers showed that during lipoplex 
formation, there exists a major structural rearrangement that yields three different 
structural configurations (complexes contained DOTAP as the cationic lipid). Figure 
3.1 shows the structure of the lamellar, the inverted hexagonal and the hexagonal 




Figure 3.1: Schematic representation of the three different structural phases (a) the 
lamellar structural phase (LCα); (b) the inverted hexagonal structural phase (H
C
II); and 
the hexagonal structural phase (HI) of a lipoplex (Ewert et al., 2006).  
 
 
The lamellar phase exists such that the DNA rods are sandwiched between the lipid 
bilayers. This phase differs drastically from the inverted hexagonal and the 
intercalated hexagonal structural phase. As displayed in Figure 3.1 (b) in the inverted 




arranged on a hexagonal lattice. In contrast, in the hexagonal structural phase the 
DNA rods are coated by three honeycombs of lipid micelles that are also arranged on 
a hexagonal lattice. It has been shown that the lamellar structural phase is present 
during liposome:DNA condensation and its subsequent transportation to the cell 
membrane (Hulst et al., 2004). However, immediately after contact with the cell 
membrane, the lipoplex transitions into the inverted hexagonal structure (Zabner et 
al., 1995).  
 
The number of amine groups (+) on the cationic lipid in relation to the number of 
phosphate groups (-) on the DNA gives rise to the charge ratio.  It has been suggested 
that a charge ratio of 1:1 lipid/DNA (neutral charge) must be avoided since the neutral 
charge generates large aggregates that are >1 µm (Xu et al., 1999) and would be of 
little value in vivo. In contrast lipoplexes prepared with a net positive charge ratio 
yield large multilamellar vesicles that possess a diameter of approximately 300-700 
nm. These lipoplexes have been shown to be more successful in transfecting cells than 
small unilamellar vesicles (SUV) which are approximately 50-200 nm in size (Simões 
et al., 2005) in vitro. The size of the lipoplex is pivotal since the complexes must be < 
150 nm in order to extravasate from the capillaries and reach their specified target 
cell.  The final size of the lipoplex is proportional to the mass of the nucleic acid 
compacted by the vector (Simões et al., 2005; Uddin, 2007).  
 
For our own investigations prepared cationic liposomes were mixed with plasmid 
DNA (pDNA). The resulting lipoplexes were further characterized according to their 
morphology and degree of protection conferred against serum nuclease digestion. 
Agarose gel electrophoresis was employed to examine the electrostatic interactions 
between the cationic liposome (positively charged) and the anionic DNA, which 
results in the binding and subsequent compaction of the nucleic acid in the lipoplex. 
The degree of protection conferred to the DNA, against serum nucleases, was 
assessed using the nuclease protection assay.  The presence and the morphology of the 








3.2. MATERIALS AND METHODS 
 
 
3.2.1. Materials  
 
 
2-[4-(2-hydroxyethyl)-1-piperazinyl] ethanesulphonic acid (HEPES), Tris-HCl and 
EDTA were purchased from Merck, Damstadt, Germany. FBS was purchased from 
Highveld Biological, Lyndhurst, South Africa. The pCMV-Luc plasmid was 
purchased from Plasmid Factory, Bielfeld, Germany. The molecular biological grade 
agarose was purchased from Bio-Rad Laboratories, California, USA. Lysozyme was 
purchased from Sigma Chemical Company, St Louis, MS, USA. All other reagents 
were of analytical grade. 
 
 
3.2.2. Methods  
 
 
3.2.2.1. Gel Retardation Assay 
 
 The gel retardation assays allow one to establish the ratio at which the plasmid DNA 
is completely bound to the cationic liposome.   
 
A 1 % agarose gel was prepared by dissolving 0.2 g of agarose in 18 Mohm water. 
The solution was brought to boil and then placed on the bench top to cool to 
temperature of 75 oC (the temperature was determined using a thermometer). Once 
the solution had cooled to the desired temperature, 2 ml of 10 x electrophoresis buffer 
and ethidium bromide (final concentration 1 µg/ µl) was introduced into the agarose 
gel mixture. The gel was allowed to set for a minimum of 60 minutes.  
 
A standard amount of pCMV-Luc DNA (0.5 µg) was added to an increasing amount 
of cationic liposome (0,2,4,6,8,10,12,14 µg), in separate micro-centrifuge tubes. The 
samples were made up to a final volume of 12 µl with HBS (20 mM HEPES, 150 mM 
NaCl, pH 7.5) and incubated for 30 minutes at room temperature. Each sample was 
vortexed and centrifuged for 30 seconds in an Eppendorf microcentrifuge (12 000 




0.05 % bromophenol blue and 0.05 % xylene cyanol) was added to all tubes. The 
samples were then subjected to electrophoresis in a Bio-Rad mini-sub electrophoresis 
tank containing electrophoresis buffer (36 mM Tris-HCl, 30 mM sodium phosphate, 
10 mM EDTA at a pH of 7.5), for 60 minutes at 50 volts. Following electrophoresis, 
the gel was viewed under UV transillumination (300 nm) and images were captured 
using a Vacutec Syngene G: Box gel documentation system.  
 
 
3.2.2.2. Nuclease Protection Assay 
  
Lipoplexes were prepared, incubated with serum and analysed using the nuclease 
protection assay to determine the degree of protection conferred by the lipid to the 
DNA.  Varying amounts of cationic liposome (as illustrated in Table 3.2 below) were 
added to a constant amount of pCMV-Luc DNA (0.5 µg).  The volume in each sample 
tube was made up to 10 µl with HBS, vortexed and centrifuged for 30 seconds and 
then incubated for 30 minutes at room temperature. Foetal bovine serum (FBS) was 
thereafter added to the complexes to a final concentration of 10 % (v/v). Two controls 
were used in this assay, a negative control using only pCMV-Luc plasmid and a 
positive control containing pCMV-Luc DNA and FBS. The tubes were then incubated 
for 4 hours, in a 37 ˚C water bath. Following incubation, ethylenediaminetetraacetic 
acid (EDTA) was added to all tubes, except the negative control (pCMV-Luc and 
liposome only), to a final concentration of 10 mM. This step was carried out as to stop 
the nuclease reaction. Sodium dodecyl sulphate was thereafter added to all tubes 
except the negative control, to obtain a final concentration of 0.5 % (w/v). Tubes were 
then incubated in a 55 ˚C water bath, for 20 minutes. Thereafter, 4 µl of the gel 
loading buffer was added to all tubes and the samples were subjected to agarose gel 
electrophoresis (as outlined in section 3.2.2.1 above), for 2 hours at 50V. Gels were 
then viewed and the images were captured using Vacutec Syngene G: Box gel 









Table 3.2: Liposome:DNA ratios analysed using nuclease protection assays. 
 
Liposome Liposome Amount (µg) DNA (µg) 
C1 1 2 3 0.5 
C2 2 3 4 0.5 
MS1 1 2 3 0.5 
MS2 3 4 5 0.5 
NN1 3 4 5 0.5 
NN2 2 3 4 0.5 
WT1 4 5 6 0.5 










Approximately 100 µl of JM109 cell suspension and 10 µl of the pCMV-Luc control 
vector solution (1 µg) was pipetted into a microcentrifuge tube, and placed on ice for 
30 minutes. Thereafter the tube was incubated in a 42 ˚C water bath for 90 seconds, 
followed by further incubation on ice for 2 minutes (transformed cells). The contents 
of the microcentrifuge tubes were then added to the LB broth containing ampillicin, 
and incubated on a 37 oC shaker for 48 hours.  
 
 
3.2.2.3.2. DNA isolation 
 
The broth containing cells were decanted into 4 centrifuge tubes (50 ml) and were 
centrifuged at 12 000 rpm for 15 minutes at 4˚C. The supernatant was then removed 
and discarded.  Cells were re-suspended in 6 ml of freshly prepared lysis buffer (25 
mM Tris-HCl (pH 7.5), 10 mM EDTA, 15 % sucrose, 25 mg/ml lysozyme). The tubes 
were thereafter placed in ice water for 20 minutes. This was followed by the addition 




carefully by gentle inversion several times (not vortexed).  Approximately 7.5 ml of 
potassium acetate (5 M) solution, pH 4.8 was added to each tube and mixed carefully 
by inversion. The tubes were thereafter incubated in ice water for 10 minutes. The 
tubes were then centrifuged at 12 000 rpm for 15 min and the supernatant was 
transferred to a fresh tube, avoiding the white precipitate. Approximately, 50 µl of 
RNase A (1mg/ml stock) was added to the supernatant in each tube. The tubes were 
then incubated for 20 min at 37 ˚C. One volume of TE buffer (10 mM Tris-HCl and 1 
mM EDTA) saturated phenol-chloroform-isoamyl alcohol (24:1 v/v) was added to 
each tube and the tubes were centrifuged at 12000 rpm for 10 minutes. The upper 
aqueous phase was saved and the above step was repeated. One volume of 
chloroform-isoamyl alcohol (24:1 v/v) was added to each tube, which were then 
vortexed for 1 min and centrifuged at 12000 rpm for 20 minutes. The supernatant was 
then removed and the resultant pellet washed with 70% ethanol by centrifugation at 
12000 rpm for 5 min. The pellet was thereafter dried under vacuum. The pellet was 
then dissolved in water and the DNA concentration and purity was analysed using a 
ThermoScientific Nanodrop 2000c spectrophotometer (Wilmington, USA) and 




3.2.2.4. Transmission Electron Microscopy (TEM) 
 
Characterization of the cationic liposome:DNA complexes was carried out in 





3.3. RESULTS AND DISCUSSION 
 
 
3.3.1. Gel Retardation Assay 
 
Lipoplex formation between the cationic liposome and the DNA was analysed by 
varying the cationic lipid to pCMV-Luc DNA ratio, using the gel retardation assay. 
The assay determined the ability of the cationic liposome to completely bind to the 


















Figure 3.2: Gel retardation assay. Reaction mixtures (14 µl) consisted of pCMV-Luc 
DNA (0.5 µg) and an increasing amounts of the non-PEGylated cationic liposome, in 
HBS. DNA: cationic liposome ratio (w/w): Lane 1-8 (1:0, 1:2, 1:4, 1:6, 1:8, 1:10, 1:12, 
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Figure 3.3: Gel retardation assay. Reaction mixtures (14 µl) consisted of pCMV-Luc 
DNA (0.5 µg) and an increasing amounts of the 2 % PEGylated cationic liposome. 
DNA: cationic liposome ratio (w/w): Lane 1-8 (1:0, 1:2, 1:4, 1:6, 1:8, 1:10, 1:12, 1:14). 
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Mass (mg) Retardation Charge ratio* 
(DNA:Liposome) 
(-:+) 







C1 1.26 1.5 - - 2 1:4 1:1.0 
C2 1.26 1.5 - 0.56 3 1:6 1:1.2 
MS1 1.26 1.19 0.22 - 2 1:4 1:1.0 
MS2 1.26 1.0 0.22 0.56 4 1:8 1:1.8 
NN1 1.26 1.19 0.26 - 4 1:8 1:2.1 
NN2 1.26 1.0 0.26 0.56 3 1:6 1:1.4 
WT1 1.26 1.19 0.28 - 5 1:10 1:2.6 
WT2 1.26 1.0 0.28 0.56 3 1:6 1:1.4 
 
*End point ratios. In calculating the nitrogen:phosphorous (N/P, positive:negative) ratio, MS09 is 
assumed to carry one positive charge at physiological pH and each nucleotide in DNA is assumed to 




The gel retardation assay is a mobility shift assay performed using agarose gel. As 
mentioned before this assay is used to investigate the ability of the cationic charge 
present on the liposomal surface, to neutralize the anionic charge of the phosphate 
backbone, producing electroneutral complexes that are unable to migrate during 
electrophoresis (Huang et al., 1998). Gene delivery by a lipid based vector can only 
be achieved when DNA is complexed to the vector. The above results (Figure 3.2 and 
3.3) show that the cationic lipid completely condensed the anionic DNA. In each of 
the images above (Figure 3.1 A, B, C, D and Figure 3.2 A, B, C, D), lane 1 represents 
a negative control (DNA only). The negatively charged DNA migrates easily towards 
the cathode during electrophoresis exhibiting the three conformations of undigested 
DNA, viz. supercoiled, closed circular and linearized DNA. The supercoiled DNA 




of closed circular and linearized DNA.  Upon the addition of an increasing amount of 
cationic liposome across lanes 2-8, the amount of DNA that migrates freely through 
the agarose gel decreases. Thus the amount of migrating DNA is suggested to be 
inversely proportional to an increase in the cationic liposome. The migration of the 
pCMV-Luc DNA will continue to decrease until the negatively charged DNA is 
completely bound to the cationic liposome.  This is known as the optimal binding 
ratio and it is the point at which the complex is electroneutral. Lipoplexes were 
assembled at or close to electroneutrality to minimize ligand-receptor interactions 
whilst minimizing non-specific electrostatic interactions with the negatively charged 
plasma membrane. This was evident in competition experiments (Figure 4.11) where 
transfection levels dropped by more than 95% in the presence of the competing 
ligand, asialofetuin.  
 
The optimal binding ratios obtained for each of the liposomal formulations are 
documented in Table 3.3 above. Non-PEGylated liposomal formulations NN1 and 
WT1 required a larger amount of lipid than their PEGylated counterparts, to optimally 
bind the negatively charged DNA (binding ratios for NN1 and WT1 are1.8 and 1.10 
respectively, with the counterparts NN2 and WT2 both binding the DNA at a ratio of 
1:6 DNA:cationic liposome). PEGylated MS2 required twice the amount compared to 
its non-PEGylated counterpart to optimally bind the anionic DNA.  
 
It has been suggested that electrostatic interactions that occur during lipoplex 
formation, impact on the organization of the solvent present around the complex. This 
leads to the restriction on the number of sites exposed for pDNA binding (Ferrari et 
al., 2001). Thus this shielding of binding sites could provide justification for some 
complexes displaying a high binding ratio whilst others display a low cationic 
liposome:DNA binding ratio. Furthermore, targeting ligands possess lipids that form 
part of the lipid bilayer, and head groups that protrude from the bilayer of the 
liposome (structural representations shown in Chapter 2.3.3). It is possible that these 
protruding groups may also block or shield other binding sites on the liposomal 
surface. Therefore, sites may be available for DNA binding but due to the restriction 
and blockage caused by the structural arrangements, a large amount of lipid will be 
required to bind the DNA. This contrasts with the length of the spacer in liposomal 




MS. Thus MS requires a smaller amount of cationic liposome to bind the pCMV-Luc 
DNA while WT1 and NN1 both require more lipid to completely bind the DNA. 
 
Optimal binding ratios obtained using the gel retardation assay, have been considered 
in assembling lipoplexes for cytotoxicity and transfection studies, in both the HEK293 















































Figure 3.4: Nuclease protection assay of cationic liposome/DNA complexes. Plasmid 
pCMV-Luc DNA (0.5 µg) completely bound to the liposomal formulations, were 
incubated in the presence of 10 % serum. Lane 1- pCMV-Luc DNA, lane 2- pCMV-
Luc DNA in the presence of serum. 
 
A) Lane 3-5 C1,  Lane 6- 8 Pegylated C2   
B) Lane 3-5 MS1, Lane 6-8 Pegylated MS2 
C) Lane 3-5  NN1,  Lane 6-8 Pegylated NN2 
D) Lane 3-5 WT1, Lane 6-8 Pegylated WT2 
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In the present study we evaluated the role played by cationic liposomes in protecting 
the negatively charged DNA.  As mentioned before, when the liposome bound DNA 
complex enters the bloodstream, the complex is subjected to nucleases present in the 
serum. The ability of a liposome to protect the DNA is undoubtedly the most crucial 
feature affecting its biological activity. To assess the complex’s degree of resistance 
to degradation by serum nucleases, lipoplexes were prepared at specific ratios (as 
outlined in Table 3.2 above) and incubated with serum. The assay mimics an in vivo 
system thus determines the capability of the lipoplex to prevent degradation by serum 
nucleases. The serum:lipoplex mixture was then subjected to agarose gel 
electrophoresis (Figure 3.4).  
 
As indicated previously, a negative and positive control, were employed for this 
assay. The negative control using only pCMV-Luc DNA is represented in lane 1 of 
Figure 3.3 (A-D) and demonstrates the migration of undigested DNA. The positive 
control containing pCMV-Luc and 10 % FBS is represented in lane 2 of Figure 3.4 
(A-D) which displays the fate of naked DNA in the presence of 10 % serum. Both 
controls are used to establish the extent of protection offered to the DNA by the 
cationic liposome. From the results above (Figure 3.4) lanes 3-8 in each image 
indicate the migration of the lipoplex bound DNA following incubation with 10 % 
serum. When lanes 3-8 are compared to lane 1 and lane 2 (negative and positive 
control) we can conclude that all cationic liposomal formulations (at, below and 
above electroneutrality) displayed a high degree of protection to the plasmid DNA, 
when subjected to 10 % serum. This is consistent with earlier findings (Kawakami et 
al., 2007) that show that complexes prepared to afford a neutral charge are capable of 
DNA protection. It is important to note, however, that the lipoplex-bound DNA is 
largely in the relaxed closed circular form after incubation with serum indicating 
some nicking of the plasmid. Similarly complexes prepared with an excess positive 
charge are capable of fully condensing DNA to form a complex that is highly resistant 
to DNase 1. In contrast, complexes that possess a net negative charge offer little or no 
protection to the DNA.    
 
The protection of plasmid DNA by the liposome could be attributed to the stability of 
the complexes or to the electrostatic forces between the positively charged liposomes 




supramolecular structures where DNA is condensed or compacted and thus largely 
protected against nuclease degradation (Singh et al., 2006).  
 
The results obtained provide clear evidence that all cationic liposomes and PEGylated 
cationic liposomes form lipoplexes with DNA, and at or near optimal binding ratios, 
these lipoplexes afford considerable serum nuclease protection. Taking this into 
consideration, lipoplexes were subjected to in vitro transfection and later in vivo 
studies (Chapters 4 and 5). 
 
 





































Figure 3.5: Transmission electron micrographs illustrating the morphology of (A) 
untargeted cationic lipoplexes, C1 and (B) Untargeted PEGylated cationic lipoplexes, 





























Figure 3.6: The morphology of targeted cationic lipoplexes and the PEGylated 
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The size of the lipoplex is relatively heterogeneous when DNA is completely 
compacted with the cationic liposome, with an estimated diameter of 100-450 nm per 
lipoplex. Complexes prepared with a lipid-DNA charge ratio of approximately 1:1, 
yielded complexes between 350-1200 nm in diameter. These complexes present a 
better colloidal stability when compared with those demonstrating a net positive 
charge. Multilamellar liposomes form lipoplexes which have been shown to 
physically exhibit “swiss roll” type of appearance. The resulting lipoplex is practically 
unusable for systematic gene delivery due to its large size and its inability to 
disentangle at the cell surface and bind to receptors adequately (Gustafsson et al., 
1995).  
 
From the results obtained (Figure 3.5-3.6) in cryoelectron microscopy studies, it can 
be seen that the unilamellar liposomes completely condensed the negatively charged 
DNA, to yield lipoplexes in a size range that show distinct potential for target cell 



























Transfection is a term that has been associated with the delivery of nucleic acids and 
their analogues to cells, in vitro and in vivo. Therapeutic applications, specializing in 
cancer treatment, have exploited the delivery of genes, as plasmid DNA (Min et al., 
2010).  The main aim of gene therapy is to engineer a vector that can successfully 
transport exogenous DNA to a target cell and ensure high levels of transgene 
expression, in vivo. Prior to in vivo studies, formulations are evaluated in vitro to 
determine their safety and efficiency in gene delivery. The transfection efficiency of a 
vector is an approximate measure of the amount of genetic material successfully 
transferred and its subsequent transcription within a given cell (Rahau et al., 2012). 
The efficiency of liposomes to optimally transfect cells in vitro is dependent on the 
chemical and physical properties of the liposome. The chemical structure of the lipid, 
the percentage of helper lipid incorporated in the formulation and the charge ratio 
between the lipid and the DNA are factors that affect transfection efficiency of a 
given formulation. Physical properties such as the size and the structure of the 
lipoplex also play a role in efficient transfection.  Other factors governing successful 
transfection include the type and quantity of lipid used, the type of cell line and the 
cell density employed during the assay (Xin et al., 2012). 
A major challenge in systemic targeting is the inability of a gene delivery vector to 
circulate in the blood for a sufficient period of time, resulting in lower levels of cell 
toxicity and higher levels of exogenous gene delivery to targeted cells (Morille et al., 
2009). To avoid non-specific interactions, selective ligands have been incorporated 
into gene delivery systems. This generates vectors that are internalized via receptor 
mediated endocytosis (active targeting). The aim of this study was to synthesize and 
compare of three unique cationic liposomal formulations. Cell specific targeting was 
achieved by incorporating galactose (10 mole %) into the lipid bilayer of each of the 




hepatocellular carcinoma (HepG2) and the human embryonic kidney (HEK293) cell 
lines. The HepG2 cells (established in 1979 from hepatoma tissue) mimics the liver 
parenchymal cells since they synthesize and secrete several serum proteins. The cell 
line originally isolated from a liver biopsy of hepatocellular and hepatoblastoma 
carcinomas (Aden et al., 1979), displays a unique characteristic exhibiting one 
nucleus and 48-54 chromosomes/ cell (Wilkening et al., 2003). This enables the cell 
line to be an ideal candidate for the analysis of cytotoxicity and pharmaceutical 
studies, targeted to the liver (in vitro). The cell line expresses the asialoglycoprotein 
receptor and is known for its rapid internalization rate and high ligand affinity. The 
receptor is known to exhibit high affinity for the galactose located at the non-reducing 
termini of the asialoglycoprotein heteroglycan structures, thus galactose molecules 
may be grafted on to the surface of liposomes to promote their cellular uptake by 
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Figure 4.1: Schematic representation outlining the interactions between the HepG2 cell 
line and the galactosylated targeting system. The galactose moiety is recognized and 
internalized by the ASGP-R present on the HepG2 cell. The HEK293 cell line is ASGP-R 




DSPE-PEG2000, (2 mole %) was employed in the preparation of the liposomes. 
PEGylation of complexes has been shown to increase the lipoplex circulation period 
sufficiently, as to allow for the complexes to reach their target organ (Braet and 
Wisse, 2002). Liposomes are frequently studied as alternatives to toxic viral vectors. 
Due to the low levels of exogenous gene expression in vivo, an increased dosage of 
the liposomal formulation is required to increase transgene expression. An increase in 
liposomal dose consequently increases cytotoxicity (Dass and Choong, 2006). This 
can be attributed to the hydrophobic and polar domains of cationic lipids (Hongtao et 
al., 2006). Thus this study has employed the use of lipids, such as cholesterol and 
DOPE (Kawakami et al., 1998) that have been known to exhibit low levels of cell 
toxicity in vitro. Various protocols (indirect methods using chromogenic indicators) 
have been developed to determine the effect of the lipoplex on cell toxicity. The most 
common protocol is the MTT cell proliferation assay, which is based on the 
conversion of a water soluble salt, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) to an insoluble formazan. The formazan is solubilized 
and the optical density of the extract is determined at 570 nm.  
 
The cytomegalovirus (CMV) promoter has been extensively used to detect the 
expression of exogenous proteins in vitro. The pCMV-Luc plasmid DNA expresses 
the luciferase gene under the control of a CMV promoter sequence. This plasmid was 
used in all studies conducted. The cationic: pCMV-Luc DNA complexes were 
prepared at different ratios of lipid to a constant amount of pCMV-Luc and subjected 
to analyses in the HepG2 and HEK293 cell lines. The pCMV-Luc reporter plasmid 
has been utilized in this study, to assess transgene expression in two cell lines, which 
typically do not otherwise display luciferase activity. The pCMV-Luc plasmid DNA 
encodes the firefly luciferase gene. This ATP-dependent gene was initially isolated 








Figure 4.2: Basic schematic representation of the pCMV-Luc DNA control vector 




The degree of cytotoxicity and transfection were measured and compared between the 
two cell lines, for all liposomal formulations, at different lipid: plasmid DNA ratios. 
The formulations displaying the highest transfection activity were subjected to the 
competition assay in an attempt to confirm that the galactosylated lipoplexes were 
actually internalized by ASGP-R mediation. The formulation showing the greatest 














HepG2 cells and foetal bovine serum (FBS) were obtained from Highveld Biological 
(PTY) LTD., Lyndhurst, South Africa. HEK293 cells were obtained from University 
of Witwatersrand, Johannesburg, SA. Minimum Essential Medium (MEM), Trysin-
versene and penicillin/streptomycin mixtures were purchased from Lonza 
BioWhittaker, Walkersville, USA. All tissue culture plastic consumables were 
purchased from Corning Incorporated, New York, USA. The Luciferase Assay kit 
was purchased from the Promega Corporation, Madison, USA. The Bicinchoninic 
acid (BCA) used in the BSA protein assay was purchased from the Sigma-Aldrich 
Co., St. Louis, USA. 2-[4-(2-hydroxyethyl)-1-piperazinzyl] ethanesulphonic acid 
(HEPES), 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and 
Phosphate buffered saline (PBS) tablets were purchased from Merck, Darmstadt, 





4.2.2.1. Preparation of tissue culture medium 
 
To Minimum Essential Medium (MEM) was added penicillin G and streptomycin to a 
final concentration of 100 u/µl and 100 µg/µl respectively.  Finally the FBS was 
added (10 % by volume). 
 
4.2.2.2. Cell maintenance and culture 
 
All media preparation and other cell culture work performed for this study, was 
executed in a class II Biohazard laminar flow hood. The cell lines (HepG2 and 
HEK293) were frequently inspected for contamination and the growth patterns 




confluency. Cells were cultured in 25 cm2 flasks and routinely spilt 1:3 every 4-5 
days.    
 
4.2.2.3. Reconstitution of the cell lines, HepG2 and HEK293 
 
Cells are cryopreserved as per standard procedures, in cryogenic vials and stored 
temporarily in a - 80 ˚C Biofreezer. Upon reconstitution of the appropriate cell line 
(HepG2 and/or HEK293), the previously cyropreserved vial containing cells are 
removed from the Biofreezer and thawed in a 37 ˚C water bath. Once the medium 
containing cells had completely thawed, the cryogenic vial was wiped thoroughly 
with 70 % ethanol and placed into the laminar flow hood. The vial was thereafter 
opened aseptically, and decanted into a 15 ml centrifuge tube. The tube was then 
centrifuged at 3000 rpm for 30 seconds. Under sterile conditions, the centrifuge tube 
was opened and the supernatant (old medium) was discarded. The remaining pellet 
was resuspended with 1 ml of freshly prepared complete medium (MEM, antibiotics 
and 10 % FBS). The tube was then vortexed for a few seconds to ensure that the 
pelleted cells were completely resuspended in the medium. Cells were thereafter 
transferred to 25 cm2 flask containing 4 ml of complete medium and incubated at 37 
˚C to allow cells to attach to the bottom of the flask. Cells were monitored on a daily 
basis and the medium changed every 2 days and replaced with fresh complete 




4.2.2.4. Propagation of Cells (HepG2 and HEK293 cell lines) 
 
When the cells reached confluency/ semi-confluency, they were trypsinized to be used 
in cell assays or spilt into 2 flasks (25 cm2). The process of trypsinization firstly 
involves, discarding the medium that is present in the flask, and washing the attached 
cells with 5 ml PBS (phosphate buffered saline) (150 mM NaCl, 2.7 mM KCl, 1 mM 
KH2PO4, 6 mM Na2HPO4; pH 7.5). The excess PBS was then discarded into the waste 
bottle. Thereafter, 1 ml of trypsin-versene was added to the flask containing the cells, 
and cells were observed under a Nikon TMS inverted light microscope for rounding 




complete medium was added to the flask. Essentially, it is necessary that 20 % of FBS 
is added to the flask since this terminates the action of the trypsin (prolonged 
exposure to trypsin could result in cell death). The flask was then tapped against the 
palm of the hand to dislodge the cells. The cells were then resupended using a 2 ml 
pipette and thereafter either divided into sterile culture flasks containing 5 ml of 
complete medium or plated in multi-welled plates, for culture assays. Cells were 
continuously monitored with regular mediun change. Once the cells had reached the 
state of confluency, they were trypsinized and spilt once again, and used for assays or 
cryopreserved.   
 
 
4.2.2.5. Cryopreservation of Cells 
 
The cryopreservation protocol is similar to that of the propagation of cells. The cells 
were trypsinized as described in section 4.2.2.4, above. Upon the addition of trypsin, 
the cells are dislodged, resuspended and transferred to a 15 ml centrifuge tube. The 
tubes were then centrifuged at 3000 rpm for 1 minute and the supernatant was 
discarded. Complete medium (0.9 ml) and dimethylsulfoxide (DMSO) (0.1 ml) was 
then added to the pelleted cells. The tube was then gently vortexed to resuspend the 
cells, in the complete medium containing 10 % DMSO. The suspension was then 
immediately aliquoted into cryogenic vials, labelled and placed in a cryogenic 
container in the biofreezer for slow freezing (1 ˚C/minute).   
 
 
4.2.2.6. Growth Inhibition Studies 
 
Upon confluency, the cells were trypsinized (section 4.2.2.4) and seeded into a 48 
well plate (cell density = 1.2 x 104 cells/well). The plate was sealed with para-film, 
appropriately labelled and incubated in a 37 ˚C incubator for 24 hours at 37 ˚C, to 
allow the cells to attach to the base of each well. Following this incubation, the 
lipoplexes (cationic liposome-DNA complexes) were prepared as per Table 3.2. The 
volume of each lipoplex suspension was then brought up to a final volume of 10 µl 




microcentrifuge, 3 000 rpm) and incubated for 30 minutes at room temperature. 
Assays were conducted in triplicate.  
 
Thereafter the old medium was removed and replenished with 0.25 ml of serum free 
medium containing antibiotics (penicillin G and streptomycin). The lipoplexes were 
then added to the appropriate wells and the plate was incubated for 4 hours at 37 ˚C.  
Thereafter the serum free medium was removed and replaced with 0.25 ml complete 
medium and the plate was incubated for 48 hours at 37 ˚C. Following the incubation 
period, the medium was removed and 0.2 ml of complete medium and 0.2 ml of the 
MTT solution (5 mg / ml PBS) was added to each well and the plate was incubated at 
37 ˚C for 4 hours to allow for the production of formazan crystals. Thereafter the 
MTT solution and medium in each well was removed and discarded. The formazan 
crstals were then dissolved by the addition of 0.2 ml of dimethylsulfoxide (DMSO) to 
each well and incubated for 5 minutes. The DMSO extract (0.1 ml) was removed from 
each well and transferred to a 96 well plate. The samples were read in a Mindray 96A 
microplate reader (Vacutec) using DMSO as the blank. The 100 % viability value was 
obtained from the OD 570 value measured for cells, without complexes. Test samples 
were measured relative to untreated cells. Viability = Test OD570 - Blank OD570______            




4.2.2.7. Transfection  
 
4.2.2.7.1. Luciferase Assay  
 
Confluent cells were trypsinized and seeded into a 48 well plate, at a seeding density 
of, 1.9 x 104 cells/well. Cells were incubated overnight, at 37 ˚C, to allow the cells to 
attach to the base of each well. Once attachment was confirmed by microscopic 
observation, the appropriate lipoplexes were prepared as per Table 2.2 and allowed to 
incubate at room temperature for 30 minutes. The medium present in each well in the 
plate, was removed and replaced with serum free medium (0.25 ml). Following the 30 
minute incubation period, the complexes were added to their appropriate wells. 




containing only the cells, and the other containing cells plus naked pCMV-Luc DNA 
(1 µg). The plate was then incubated for 4 hours in a 37 ˚C incubator. Thereafter the 
medium was removed and replaced with 0.25 ml complete medium (MEM + 10 % 
foetal bovine serum) and cells incubated for a further 48 hours, at 37 ˚C.  
 
The luciferase assay was carried out using the Promega Luciferase Assay kit. The 5x 
lysis reagent (25 mM trisphosphate, pH 7.8, 2 mM dithiothreiotol, 2 mM 1,2-
diaminocyclohexane-N, N, N’N’-tetraacetic acid, 10 % (v/v) glycerol, 1 % (
v/v) Triton 
X-100) was allowed to thaw at room temperature. This was then diluted with distilled 
water to obtain a 1x stock.   
 
The medium from the wells were then removed and the cells were washed twice with 
PBS (approximately 0.1 ml). A total volume of 80 µl of 1x cell lysis reagent was 
added to each well. The plate was placed on a mechanical platform shaker (Scientific 
STR 6, Surrey, UK), for 15 minutes at 30 rev / min. The cells were finally dislodged 
from the bottom of each well, by scrapping the base of each well with either a pasture 
pipette or the tip of a micropipette. The resulting cell solution was dispensed into 
microcentrifuge tubes and centrifuged at 12 000 rpm for 30 seconds. The clear 
supernatant, containing the cell free extract, was subjected to luciferase activity 
analyses. This involved the addition 100 µl of luciferase assay reagent to 20 µl of the 
cell free extract. This was immediately mixed and placed in the Lumac Biocounter 
1500 luminometer (Landgraaf, Netherlands). The cell free extract was also subjected 
to the bicinchoninic acid (BCA) assay to determine protein content.      
 
 
4.2.2.7.2. Competition Assay 
 
Confluent cells were trypsinized and seeded into two 48 well plates (2 x 104 cells/well 
and 2.5 x 104 cells/well) and incubated at 37 ˚C, for 24 hours to allow the cells to 
adhere to the base of each well. The appropriate lipoplexes were prepared as per 
Table 3.2 and allowed to incubate at room temperature for 30 minutes. The assay was 
carried out in triplicate. The medium from each well was removed and replaced with 
serum free medium (0.25 ml). Thereafter 25 µl of asialofectuin (Stock of 10 µg/ µl) 




complexes were then added to each well and the plate was incubated for 4 hours, at 37 
˚C. Thereafter the medium was removed and replaced with 0.25 ml complete medium 
(MEM + 10 % foetal bovine serum) and cells incubated for a further 48 hours at 37 
˚C. The luciferase assay was conducted as described in Section 4.2.2.7.1 above.  
       
4.2.2.7.3. Statistical Analysis 
A comparison between each of the positive controls and the respective test groups 
was analysed using the unpaired student t-test. A p-value of < 0.05 was considered as 
significant in this study.  
 
 
4.3. RESULTS AND DISCUSSION 
 
4.3.1. Growth Inhibition Assay 
 
Cytotoxicity induced or caused by lipoplexes is an obstacle in gene therapy and 
cytotoxicity studies are used to determine the safety of the liposomal formulations in 
vitro and potentially in vivo. The MTT Assay is a simple method used to determine 
cell numbers spectrophotometrically. This assay was used to evaluate the effects of 
the lipoplex on cell survival. The assay was carried out using the ASGP-receptor 
negative cell line, HEK293 and the ASGP-receptor positive cell line, HepG2. The 
results obtained are shown below in, Figures 4.3-4.6. 
 
 
4.3.1.1. HepG2 and HEK293 Cell line  
 
From the results obtained, all cationic liposome:DNA complexes analysed were well 
tolerated over the entire lipid concentration range (3-11 µg/10 µl). The study findings 
are in agreement with those of Percot et al. (2004), who showed that galactosylated 
cationic liposomes, containing DOPE, displayed low toxicity in the HepG2 cell line. 
Nguyen and co-workers (2007) also showed that there existed a distinct synergy 
between the plasmid DNA and the cationic lipid, which undoubtedly resulted in the 
cell toxicity. It was found that free naked DNA did not induce cell death, however 




slightly induced cytotoxicity. Cell death was further increased when the cationic lipid 











































































Figure 4.3: MTT cytotoxicity assay in HepG2 cells. Assay was conducted in a 48 
well plate with 1 µg pCMV-Luc DNA/well and an increasing amount of the liposomal 
formulation, as indicated in each case above. (A) untargeted liposomal formulation 
C1; non-PEGylated formulations (B) MS1 (C) NN1 (D) WT1. Results are represented 




































































































































Figure 4.4: MTT cytotoxicity assay in HepG2 cells. Assay was conducted in a 48 
well plate with 1 µg pCMV-Luc DNA/well and an increasing amount of the liposomal 
formulation, as indicated in each above. 2 mole % PEGylated (A) untargeted C2; (B) 































































































































Figure 4.5: MTT cytotoxicity assay in HEK293 cells. Assay was conducted in a 48 
well plate with 1 µg pCMV-Luc DNA/well and an increasing amount of the liposomal 
formulation, as indicated in each above. (A) Untargeted liposomal formulation, C1; 
non-PEGylated targeted formulations (B) MS1; (C) NN1; (D) WT1. Results are 
































































































































Figure 4.6: MTT cytotoxicity assay in HEK293 cells. Assay was conducted in a 48 
well plate with 1 µg pCMV-Luc DNA/well and an increasing amount of the liposomal 
formulation, as indicated in each above. 2 mole % PEGylated (A) untargeted C2; (B) 





























































There are various factors affecting toxicity of lipoplexes, and these include the nature 
of the cationic lipid, the zeta potential, time of incubation, type of cell line and cell 
density (Dass et al., 2004). Is has been suggested that cell toxicity caused by cationic 
lipids is due to an increase in cell membrane permeability as well as the creation of 
transmembrane pores (Singh et al., 2006). Multivalent cationic compounds (such as 
2,3-dioleoyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propaniminium 
trifluoroacetate) are known to induce toxicity since they form aggregates with 
intracellular organelles, resulting in cell death. Amino acid-based cationic lipids, in 
contrast, easily dissociate and are metabolized within the cell and thus are less toxic 
(Obata et al., 2008).  
 
Maximum growth inhibition of untargeted non-PEGylated and PEGylated cationic 
liposomes in the HepG2 cell line was 12-27 % and 26-40 %, respectively (Figures 
4.3-4.6). The untargeted formulations, C1 and C2, showed minimal toxicity with the 
untargeted, non-PEGylated complex, displaying a slight increase (1%) in cell survival. 
The receptor negative cell line displayed a similar degree of cell death with the 
respective liposomal formulations, with the untargeted PEGylated and non-PEGylated 
cationic liposomes exhibiting 15-38 % and 21-38 % cell death, respectively. In both 
the cell lines, the targeted PEGylated liposomal formulation showed a greater degree 
of cytotoxicity than their non-PEGylated counterparts. A recent study (He et al., 
2009) on nanoparticles using the Chang cell line, established that an increase in the 
molecular weight of PEG is closely related to an increased in cell toxicity. Thus the 
findings in this study, with respect to increase toxicity in the PEGylated liposomes, 
can possibly be attributed to the presence of the PEG component in the formulation.  
 
 
4.3.2. Luciferase Assay 
 
In the presence of ATP and Mg2+, the firefly luciferase produces light from the 
subtrate luciferin. The ATP dependent reaction is achieved by the oxidative 
decarboxylation of the beetle luciferin, resulting in the emission of light  at a 
wavelength of 562 nm. Transient gene expression was measured with assemblies 
containing 3-11 µg/10 µl liposome, using the luciferase assay, in the HepG2 and 























































































Figure 4.7: Luciferase transfection  assay in the ASGP-R positive cell line, HepG2. Assay was conducted in 
a 48 well plate with 1 µg pCMV-Luc DNA/well and an increasing amount of liposome (as indicated above). 
(A) untargeted liposomal forumaltion, C1; non-PEGylated targeted formulations (B) MS1; (C) NN 1; (D) 
WT1. Results are presented as means ± S.D (n=3). Significant statistical difference of transfection between 




























































































































































Figure 4.8: Luciferase transfection  assay in the ASGP-R positive cell line, HepG2. Assay was conducted in 
a 48 well plate with 1 µg pCMV-Luc DNA/well and an increasing amount of liposome (as indicated above). 
2 mole % PEGylated (A) untargeted C2; (B) MS2; (C) NN2; (D) WT2. Results are presented as means ± 
S.D (n=3). Significant statistical difference of transfection between the lipoplexes and the control are 
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Figure 4.9: Luciferase transfection  assay in the ASGP-R  negative cell line, HEK293. Assay was 
conducted in a 48 well plate with 1 µg pCMV-Luc DNA/well and an increasing amount of liposome (as 
indicated above). (A) untargeted liposomal forumaltion, C1; non-PEGylated targeted formulations (B) MS1; 
(C) NN1; (D) WT1. Results are presented as means ± S.D (n=3). Significant statistical difference of 




























































































































































Figure 4.10: Luciferase transfection  assay in the ASGP-R negative cell line, HEK293. Assay was 
conducted in a 48 well plate with 1 µg pCMV-Luc DNA/well and an increasing amount of liposome (as 
indicated above). 2 mole % PEGylated (A) untargeted C2; (B) MS2; (C) NN2; (D) WT2. Results are 
presented as means ± S.D (n=3). Significant statistical difference of transfection between the lipoplexes and 



































































Table 4.1: Summary of luciferase activity detected in each cell line for the respective 
liposomal formulations.  
 





HepG2 Cell line 
 
HEK293 Cell line 
 
C1 1:3 14413 824 
 1:4 19565 689 
 1:5 30800 1492 
C2 1:5 10000 284 
 1:6 21063 937 
 1:7 112333 1193 
MS1 1:3 226819 293 
 1:4 239360 424 
 1:5 156490 326 
MS2 1:7 965666 1000 
 1:8 409800 1310 
 1:9 90467 431 
NN1 1:7 439707 159 
 1:8 319513 155 
 1:9 208185 206 
NN2 1:5 93460 131 
 1:6 132531 142 
 1:7 85293 168 
WT1 1:9 707195 165 
 1:10 2030200 219 
 1:11 1919378 175 
WT2 1:5 1157067 149 
 1:6 155160 173 







The galactosylated cationic liposomal formulations analysed in this study, showed varying 
degrees of transfection activity, when subjected to the luciferase assay (Figures 4.7-4.10). 
The transfection activities were measured in the galactose receptor positive cell line, HepG2 
and the receptor negative cell line, HEK293. Results that were considered statistically 
significant, exhibited a p value below 0.05 (student t-test). Furthermore, each assay plate 
contained two controls, cells alone and cells with pDNA only. The two controls showed low 
luminescence levels in both of the cell lines. The control utilizing DNA and cells, showed a 
slight increase in luminescence when compared to the control, containing cells only (p < 
0.05, both cell lines).  This could be attributed to the fact that a small portion of naked DNA 
can gain access into the cell and be expressed.  
 
When compared to the targeted liposomal formulations, untargeted non-PEGylated and 
PEGylated liposomes, exhibited the lowest transfection activity (Table 4.1). Furthermore, 
there existed a distinct difference in the transfection activity between the two cell lines 
utilized, using targeted liposomal formulations. Luciferase activity in the HepG2 cell line 
showed an greater increase when compared to the activity measured in the receptor negative 
cell line. This clearly indicates that liposomes containing galactose (10 mole %), was 
successful in specifically the targeting hepatocytes, in vitro. The highest transfection activity 
observed, in the HepG2 cells, was obtained with the WT1 liposomal formulation (2030200 
RLU/ mg protein). This was followed by its PEGylated counterpart, WT2 (1157076 RLU/ 
mg protein). PEGylated liposomal formulations have been known to inhibit the transfer of 
DNA. It has been suggested that the presence of PEGylated chains restricts the close contact 
between the endosomal membrane and the lipids of the PEGylated liposomal complex. 
Therefore, DOPE is unable to destabilize the endosomal membrane and release the pDNA. 
As a result, the DNA is entrapped in the endosome while it fuses with the lysosome and is 
degraded. This prevents the effective delivery of the pDNA to the nucleus and thus can be 
attributed to the reduced transfection activity measure (Song et al., 2002).  
 
The liposomal formulation containing the cytofectin WT was chemicaly synthesized through 
a process called “click chemistry”. The success of a liposome to target a specific cell is 
dependent on the biochemical and physiochemical properties of the formulation (Kawakami 





Attachment of the targeting ligand and the cholesteryl anchor (MSO9) has been achieved by 
two distinct linkages; the carbamoyl link (NN and WT) and the glycosidic linkage as 
observed in the MS formulations. The distance between C1’ (anomeric carbon) of the 
pyranose ring and the C3 of cholesterol (considered the anchor point) have been assessed for 
all three formulations. The length of the spacer varies from 2.42 to 10.1 Å (Figures 2.7, 2.8 
and 2.9). An important feature of the WT formulation is the increased spacer length (Figure 
2.8) which exists between the galacto moiety and cholesteryl anchor thus displaying the sugar 
moeity more prominently therefore, allowing the nanosystem to gain access and bind the 
receptors comfortably. This is consistent with earlier findings (Kawakami et al., 1998; Singh 
and Ariatti, 2006) that an increase in the spacer length mediates higher transfection activity.  
 
When results were compared to the binding ratios, it was noted that the formulations MS1, 
NN2 and WT1 displayed the highest luciferase activity at their optimum binding ratios. In 
contrast, formulations MS2, NN1 and WT2 performed best at their sub-optimum binding 
ratio.  In the HEK293 cell line, it was observed that both the non-PEGylated and PEGylated 
formulations of MS and WT exhibited high transfection activity at their optimum binding 
ratios, whilst the NN formulation  showed highest transfection at its supra optimum binding 
ratio. The possible explanation for the highest transfection activity achieved for each 
formualtion at varying ratios, could be associated with lipoplex size differences at different 
DNA:liposome ratios (Higuchi et al., 2006). All formulations were considered statistically 
significant from the control (cells only. The results obtained in this study clearly show that 
the transfection activity of the non-PEGylated complexes is directly proportional to an 
increase in C1-C3 spacer length. An increase in the length of spacer can increase the 
probability of the lipoplexes and their contents being taken up by the cell (Davis and 
Robinson, 2002).  
 
 
4.3.3. Competition Assay 
 
Specific targeting of lipoplexes to hepatocytes can be achieved via receptor mediated 
endocytosis (ligand-receptor interactions). The process aims to utilize the abundantly 
expressed asialoglycoprotein receptor which is unique to hepatocytes, in an attempt to 




triantennary sugar chain with galactose terminals and is known to be the natural ligand which 




Figure 4.11: Competition assay with Control (cells only), C+DNA (cells plus naked pCMV 
DNA) and lipoplexes (A) MS1; MS2 and (B) NN1; NN2; WT1; WT2 without the ASGP-R 
natural ligand or lipoplexes with the natural ligand Asialofetuin  in HepG2 cells. Assay was 
conducted in a 48 well plate with 1 µg pCMV-Luc DNA and an increasing amount of 
liposome (as indicated above). Asialofetuin concentration 25 µl per well (Stock of 10 µg/ µl). 
Results are represented as means ± S.D. (n=3). Significant statistical difference between 
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The competition assay utilizes free asialofetuin to assess and confirm the uptake of 
complexes by the ASGP-R. The free asialofetuin ligands in the test wells are bound and taken 
up by the receptors present on the HepG2 cell. This limits the percentage of ASGP-receptors 
available for the binding of the galactosylated liposomal formulations. The cells treated with 
the ligand asialofetuin prior to the addition of the galactosylated liposomal formulations, 
showed a marked and very significant (p < 0.001) decrease in transgene expression (Figure 
4.11). This strongly suggests that lipoplexes are taken up specifically and almost exclusively 





































IN VIVO ANALYSIS OF A CATIONIC LIPOSOMAL 
FORMULATION SHOWN TO MEDIATE EFFICIENT 






For efficient delivery of a therapeutic gene it is necessary to develop a vector that has the 
ability to be used successfully both in vitro and in vivo. Thus once the three cationic 
galactosylated liposomal formulations and their PEGylated counterparts were analysed in 
vitro, the most efficient formulation/s were subjected to in vivo studies. Most vectors 
developed thus far are aimed at increasing exogenous gene expression but many are only 
evaluated in vitro, using cultured cells. This is particularly problematic, since several 
vectors/formulations that were previously shown to be efficient in vitro do not exhibit high 
exogenous gene expression in vivo (Fortes and Razquin, 2009).  
 
Cationic liposomes are one of the most popular non-viral vectors used in gene therapy. These 
nanosystems exhibit desirable features such as, a net overall positive charge that allows for 
the binding to negatively charged DNA to the cell surface, for adequate internalization and 
potential transcription of the genes. Within the cell, the liposome also offers protection to the 
DNA from en-route DNases. The liposomal formulations that were subjected to in vivo 
analyses in this study displayed the following characteristics: 
 
i. a cholesterol lipid anchor that has low toxicity and promotes high gene expression, 
ii. DOPE as a co-lipid, for the initiation of endosomal fusion and enhancement of DNA 
release from the primary endosome to evade chemical degradation, 
iii. the sugar moiety, galactose for specific targeting to the liver hepatocytes via receptor 
mediated endocytosis (ASGP-R) 
iv. an increased spacer length in the spacer element resulted in increased extension of the 





v. PEGylation to provide a steric barrier to the vector and cargo (DNA) which  will 
inhibit opsonisation.  
 
These ideal characteristics found in these formulations predict that they may have the ability 
and potential to achieve in vivo delivery. However, there are many parameters underlining 
successful delivery of therapeutic gene, hence making it unfeasible to expect a parallel 
relationship to exist between the chemical features of a delivery vector and the resulting 
transfection activity (Bhattacharya and Baja, 2009). With the synthetic vector facing various 
obstacles, achieving high levels of therapeutic gene transfection, in vivo, is a major challenge.  
 
As mentioned previously, the complex must first gain access into the cell. In this study we 
have achieved cell specific targeting through the ASGP-receptor that internalizes the 
galactosylated vector carrying the DNA, facilitating expression of the transgene. The density 
of the galactose sugar on the surface of the liposome plays a crucial role in ASGP-R mediated 
uptake. The effect of galactose density was investigated by Managit and co-workers (2005). 
The group synthesized cholesten-5-yloxy-N-(4-(1-imino-2-D-thiogalactosylethyl)formamide 
(Gal-C4-Chol) and formulated it into liposomes at different molar ratios and tested the effect 
of galactose density on gene expression, in vivo via intravenous injection.  The study showed 
that liposomes galactosylated with Gal-C4-Chol (3.5 %, 5 %, and 7.5 %), rapidly disappeared 
from the blood stream and accumulated in the liver. The approximate amount of the 
liposomal formulation to have gained access to the liver was calculated to be 80% of the 
initial dose injected into the animal. Liposomal formulations containing a lower percentage of 
the Gal-C4-Chol (1 % and 2.5 %) showed liver accumulation to a lower extent when 
compared to the liposomal formulation containing a higher percentage of the Gal-C4-Chol, 
and a relatively small difference to the control liposomes containing no Gal-C4-Chol. The 
most promising outcome of the above mentioned study was the establishment of the most 
promising formulation, in terms of the galactose density. The group clearly showed that 
liposomal formulations containing 5 % Gal-C4-Chol, were most efficient in transfection, 
since these liposomes were taken up rapidly by hepatocytes. In the present study, liposomes 
formulated with galactosylated cholesteryl derivatives at the 10 mole % level, promoted very 
efficient transfection of HepG2 cells in vitro. Moreover, lipoplex cell entry was shown, in a 





Following cell surface internalization, the next crucial step is the endosomal release of the 
cargo DNA from the lipoplex, to prevent lysosomal degradation. The incorporation of DOPE 
in the formulations, results in endosome disruptions accomplished by enhanced membrane 
fusion. This results in a flip-flop of the anionic endosomal monolayer and interaction with the 
cationic liposome. The DNA disassociates itself from the liposome due to the neutralization 
of liposomal charges by interaction between the collapsed membrane and the lipid (Abbott et 
al., 2005). Only if the DNA evades degradation by serum nucleases, will the genetic material 
reach its target cells and finally the nucleus where it will undergo transcription. The 
incorporation of 2 % DSPE-PEG2000 into the formulations tested affords protection to the 
lipoplexes from the serum nucleases. Key issues facing in vivo liposomal delivery are 
induced cytotoxicity, rapid blood clearance, and inability of targeting specific cells.  
 
Administration of therapeutic exogenous genes can be accomplished via several different 
delivery routes. The abdominal cavity and the peripheral veins can be used as potential routes 
for the delivery of genetic material (Baumhofer et al., 1998 and Biewenga et al., 1995). 
Depending on the application, the administration routes employed in previous studies 
include; intravenous, intra-arterial, intratumoral, intramuscular, intraperitoneal, intrasplenic, 
intradermal, intratracheal, mucosal (nasal, rectal or vaginal), subcutaneous, subretinal and 
transdermal (Figure 5.1). Intravenous injection has been regarded as the “holy grail” for the 
delivery of therapeutic DNA (Templeton, 2001). Studies involving Glyco-poly-L-lysine, 
showed that liver targeting can be achieved in vivo, by using either intraperitoneal or 
intravenous administration (Yang et al., 2000). However, the intravenous route of 
administration results in higher transfection activity than the intraperitoneal administration 
and thus this method of gene delivery to the liver being more favourable was employed for 





















Functional properties previously defined using in vitro analyses techniques, do not measure 
or predict the resulting stability of lipoplexes, the biodistribution and pharmacokinetics in 
vivo, of which all are key aspects for successful gene transfection. Seven crucial points have 
been highlighted for the optimization of therapeutic gene delivery and it has been suggested 
that these points be investigated in detail prior to initiation of animal studies. The seven key 
issues include (but are not limited to) the plasmid DNA design and its subsequent preparation 
method and resulting purity, the formulation of the delivery vector to be used, the route of 
gene/drug delivery, the dose to be administered, the administration schedule (incubation 
time) and the method used for the detection of exogenous gene expression or the transfection 
activity (Templeton, 2001).  
 
In this case study three distinct, galactosylated cationic liposomal formulations were 
compared for their effectiveness in gene delivery, in vitro. As mentioned previously the three 
formulations were targeted specifically to the liver hepatocytes via the ASGP-R. Both 
pegylated and non pegylated galactosylated cationic liposomes were investigated, in vitro, in 
the human carcinoma cell lines, HepG2 and HEK293 (Chapter 3). The three unique galactose 
targeted liposomes prepared are: cholesteryl-3β-N – (4-aminophenyl-β-D-galactopyranosyl) 
carbamate; cholesteryl (1-β-D-galactopyranosyl-1,2,3triazol-4-yl)carbonate; cholesteryl-β-D-
galactopyranoside. Untargeted, PEGylated and non PEGylated liposomes were also 





From the results gained in vitro, the liposomal formulations WT1 and WT2 displayed the 
highest luciferase activity. The two formulations were therefore assessed for their ability to 
deliver corrective DNA to human cells, in vivo following injection via the tail vein into rats. 
The necessary organs were harvested using the method of Kawakami et al. (2000), with mild 
modifications (anesthesia of animals with Halothane).  The in vivo experimentations were 
approved, by the University of KwaZulu-Natal Ethic Committee prior to initiation of the 
animal testing (approval number: 076/11/Animal-See Appendix 3).  
 
 




All chemicals utilized were of analytical grade. A total of 16 male Sprague Dawley rats (230-





5.2.2.1. Animal Maintenance 
 
All animals were allowed free access to food and water. Cages housing the animals were kept 
clean, with the saw dust being changed once every two days. The rats were monitored twice a 
day, following the administration of test formulations.  
 
 
5.2.2.2. Preparation of test formulations 
 
Lipoplexes were prepared in accordance to Table 5.1 below, under aseptic conditions. The 




solution. This study employed two controls, i.e. animals not treated with any of the 
formulations and animals treated with naked pCMV-Luc DNA.  
 
 
Table 5.1: Preparation of different formulations, analysed in vivo.  







Control 1 - - - 
Control 2  20.00  - 20  
C2         (MSO9:DOPE)  2.75  29.0  20  
WT1     (MSO9:DOPE:GAL)  2.75  72.7  20  
WT2     (MSO9:DOPE:GAL:PEG 2000)  3.08  39.0  20  
 
 
5.2.2.3. In vivo Transfection  
 
The method used in this study was adapted, from Kawakami et al., (2000). Animals were 
selected according to weight, sex and species (230-250 g, male, Sprague Dawley rats). A total 
of 4 rats per test group (outlined in Figure 5.2) were separated and labelled appropriately. 
Two controls were employed in this study. Control 1, were untreated animals that received no 
test formulation. The control 2 group were animals receiving only pCMV-Luc DNA. Control 
2 and lipoplexes C1,   WT1 and WT2 were prepared in accordance to Table 5.1 and 
incubated for 30 minutes. The rats (maximum of 2 animals at a time) were then placed in a 
heating chamber (chamber heated by a light bulb) for 10-15 minutes. This was conducted to 
allow for the dilation of the tail vein, to assist in a quick and proper administration of the test 
formulations. After the vein dilated and was visible to the naked eye, the animal was gently 
restrained by picking up the rat with the palm of the hand placed on the back of the animal. 
Upon placing of the hand on the animal, the upper thoracic and neck region was grasped 
between the thumb and index finger. The other hand was used to gently support the animal 





The tail vein was located, disinfected with hibitane and using a 23 gauge needle, the test 
formulations were carefully injected into the tail vein on the animal. The animals were taken 
to the autopsy room and were subjected to euthanasia, 5 hours after administration of the 
formulations. A cotton gauze was soaked with anaesthetic (halothane) and placed at the 
bottom of a bell jar. The gauze was then covered with a wire mesh to ensure that the animal 
did not come into contact with the anaesthetic. The animal was carefully placed into the jar 
and covered. After the animal’s respiration stopped, the rat was removed from the jar and the 
pulse was checked to ensure that the animal was dead. The rat was then dissected and the 
required organs were harvested and placed (separately) in beakers containing ice cold Sabex 
saline solution. All tissues were placed on ice and transported to the laboratory for further 
analyses. Animal remains were incinerated by the BRU. Organs were washed with the Sabex 
solution, dried gently and weighed. Each organ was cut into tiny pieces and subjected to 
homogenization (Dounce homogenizer) following the addition of 5 µl/ mg rat tissue lysis 
buffer (2 mM EDTA, 0.1 M Tris-HCl, 0.1 % Triton X-100). The homogenate was then 
centrifuged at 4000 rpm for 10 minutes, at 4 ˚C (Figure 5.2).   
 
The lysate (20 µl) was then added to the luciferase assay reagent (100 µl), (luciferase assay 
protocol, outlined in Chapter 4, section, 4.4.1). This was mixed immediately and placed in the 
Lumac Biocounter 1500 luminometer. The cell free extract was also subjected to the 
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Animals were sacrificed following anaesthesia with Halothane, 5 hours after injecting the 





The required organs (Liver, Lung, Spleen, Kidney, Heart) were harvested and placed in 











Samples were centrifuged and subjected to the Luciferase assay 
















5.3. RESULTS AND DISCUSSION 
 
All animals used in the study showed no visible side effects or signs that the formulations 
were toxic. It is also noteworthy that no deaths were reported during the study prior to 
sacrifice. There were high expectations for high transfection in the WT1 and WT2 
formulation since both formulations displayed the key characteristics (cholesterol lipid, 
DOPE as a co-lipid, Gal targeting ligand, and PEGylation) required for high transfection 
activity.  However, after 5 attempts, both formulations showed no increased transfection 
activity in vivo, when compared to the controls. Results obtained from a representative 
experiment are shown below in Table 5.2.  
 
Table 5.2: Transfection activity for the various organs, after in vivo gene expression. Results 
are measured against the two controls.  
 
Organ Measured Luciferase Activity (RLU/ mg protein) 
Control 1 Control 2 C1 WT1 WT2 
Lung 140 143 141 151 143 
Liver 142 141 145 145 140 
Kidney 136 133 132 140 130 
Spleen 111 98 117 123 113 
Heart 68 66 68 71 60 
 
 
The method as outlined in Section 5.2.2.3 was the first attempt to analyse gene delivery in 
vivo on the UKZN Westville campus. The results portrayed above are obtained from this 
experimental attempt. Since no distinct increase in the transgene expression was noted, the 
current protocol was modified several times, with each attempt generating similar if not the 
same results. In the second attempt the homogeniser was switched from a Dounce to the Ultra 
Turrax. The Ultra Turrax allows for the increased and quick homogenization of tissue 




heart and lung that were possibly not homogenized sufficiently in the first attempt (Dounce). 
In this attempt we assumed that the high speed homogenizer would shred the tissue 
sufficiently, releasing the soluble cellular material that may be taken for the luciferase assay. 
In the third attempt 3 freeze-thaw cycles were added to the method. Again, this was carried 
out to increase membrane disruption and allow the cellular contents to be released.  
 
In the fourth attempt, the incubation time was altered from 5 hours to 24 hours. Animals were 
intravenously injected with the test formulations and were only dissected 24 hours later. It 
was reasoned that the added time would ensure hepatocyte accumulation of lipoplexes and 
promote higher transgene activity. In the final attempt the amount of pCMV-Luc DNA 
administered was increased. The DNA concentration was increased from 20 µg to 30 µg with 
the total volume being brought up to 400 µl. Although there was an increase in the total 
volume only 300 µl of the solution was injected into the animal due to weight/volume 
restrictions.     
 
In all five attempts, the liposomal formulations show no significant transfection of exogenous 
DNA in vivo. The expression of pDNA in vivo is restricted by the cell’s natural defence 
mechanisms, developed to prevent expression of toxic factors.  Studies on the effects of the 
incubation period of lipoplexes on gene transfer revealed that lipoplexes that were prepared 
within an hour of incubation proved more effective in gene transfection than complexes 
prepared in 5 hour incubations (Zhang et al., 2003). It is possible that the lipoplexes prepared 
could have been rapidly cleared from the blood and excreted from the animal thus resulting in 
no significant expression of the luciferase gene.  
 
Little or no gene expression in vivo could also be attributed to various factors including poor 
preparation techniques used during preparation of the pDNA, the sub-optimal promoter-
enhancers present in the pCMV-Luc DNA, may not be optimal for the animal models chosen 
detection and measurement of transfection activity (gene expression). Furthermore, 
intravenously administered liposomes lose their ability to bind and carry the DNA in the 
presence of serum (> 10 % serum). The negatively charged plasma serum proteins bind to the 
cationic liposome: DNA complex and destabilizes and inactivates the lipoplex. This results in 
the aggregation of the lipoplex which either precipitates out the complex or causes the 




site. Hence serum proteins have led to the reduction or inefficiency of corrective DNA 
delivery (Li et al., 2011).  
 
Initially it was postulated that PEGylation could reduce the probability of the liposome being 
taken up by the macrophages which in turn extends the circulation time and decreases 
initiation of inflammatory responses. However, it has also been shown that PEG in fact 
interferes with and inhibits the endosomal release of the DNA. The incorporation of 5 mole 
% PEG into the liposomal formulation has been shown to inhibit the disruption of the 
endosomal membrane and the subsequent release of the DNA (Song et al., 2002). This 
correlates with earlier findings by Mori et al., (1998) that established that the endosomal 
rupture was inhibited by PEGylated liposomes. Furthermore, materials are cleared from 
circulation, according to the size. Particles within 0-30 nm are cleared rapidly by renal 
excretion. Particles greater than 30 nm are cleared by the Kupffer cells and the spleen. The 
lack of activity in vivo may also be attributed to macrophage clearance.  
 
The ability of the liposome to completely condense the anionic DNA to a relatively small size 
is another element affecting gene delivery. This is because particle size impacts on the 
efficiency of the internalization via endocytosis as well as the in vivo biodistribution (Sun et 
al., 2004). Interestingly it has also been shown that glycosaminoglycans (GAG) interact with 
the cationic liposome: DNA complex inhibiting gene delivery at the cell surface by 
destabilizing the complex causing the extracellular release of the therapeutic DNA (Ruponen 
et al., 2004). This could explain the results obtained since no gene expression was detected in 
any of the organs harvested.  
 
The effects of serum (10 % v/v) on DNA liposome binding was measured on all of the 
liposomal formulations (Chapter 2), however results obtained from in vitro studies cannot 
always  be correlated to success, in vivo (Bhattacharya and Baja, 2009) as can be seen in the 
current study. Further in vivo trials and optimizations of protocols in vitro and in vivo will 







CONCLUSION AND FUTURE DIRECTIONS 
 
The perfect gene delivery vector must be a tool that boasts efficient and sustainable 
characteristics that enable the protection of the exogenous DNA from nucleases, target a 
specific cell population and have the potential to reach the nucleus in a deserved amount that 
will bring about change. Furthermore these characteristics must not only be exploited in in 
vitro studies but the vector should be capable of tolerating the extreme in vivo environment.  
 
In this study, 3 different galactosylated liposomal formulations and their PEGylated 
counterparts, were synthesized and analysed, for their gene transfer efficacy, in vitro. After 
confirming their ability to bind and protect DNA, using the gel retardation and nuclease 
protection assay, liposomes were assessed using the cultured cell lines, HepG2 and HEK 293. 
Given the structural configurations and physico- chemical properties, the liposomes showed 
promising results, with reduced levels of cell toxicity and good transfection activity, in 
cultured cells.  Furthermore, receptor-mediated endocytosis of lipoplexes via the ASGP-R 
was demonstrated using the competition assay in HepG2 cells. The liposomal formulations, 
WT1 and WT2, displayed the highest levels of targeted transfection activity in vitro that 
could be attributed to the increased length of the spacer arm in the targeting element. The two 
formulations were then subjected to in vivo studies, using rats. However, the sound results 
obtained in in vitro studies could not be correlated with the lack of positive results obtained in 
in vivo studies.  
 
Thus it has been demonstrated in vitro that an increase in the spacer length in the galactosyl 
cholesteryl derivatives correlates with higher transfection activity. This was also dependent 
on the design of the liposomal formulation and the cell line used. Furthermore, although 
liposomes show enormous potential when subjected to in vitro analysis, a better 
understanding and further optimization is required to improve the reduced potential obtained 
in the current in vivo study. More detailed investigations are required that place emphasis on 
exposure (both short and long term) in animal, humans and their environment (Malam et al., 
2009). The effect of the positively charged lipid on binding and compaction of the DNA and 
the stability of the complex in the cytosol, are key aspects that effect transfection and require 





Gene delivery is indeed a multi-ordered process that requires a multi-functional vector to 
successfully enter the cell and surmount obstacles, within the cell. Thus future studies could 
be focused on vectors such as “artificial viruses” which can be synthesized to portray 
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Spectral data of galactosylated moieties analysed in the present study. 
 
Compound:  
3β[N-(4-aminophenyl-β-D-galactopyranosyl) carbamoyl]  cholesterol (NN) 
 
IR: 3333 (m, OH, CONH); 2933, 2900, 2867 (m, CH, CH2, CH3); 1698 (m, urethane); 1603 
(m, benzene ring); 1510 (s, benzene ring); 1414 (m, O-H); 1381 (w, C(CH3)2); 1214 (s, C-O); 
1050 (s, C-OH); 833 (m, aromatic C-H) cm-1. 1H NMR (600 MHz, C5D5N, TMS): sugar 5.54 
(d, 1H, J = 6.7Hz, H-1”), 4.77 (dd, 1H,J = 9.3, 7.9 Hz, H-2”); aromatic 7.45 (d, 2H, J = 9 Hz, 
H-3’, H-5’), 7.88 (d, 2H, J = =8.2 Hz, H-2’, H-6’) sterol 0.67 (s, 3H, CH3, C-18), 0.91 (d, 6H, 
J = 6.8 Hz, CH3, C-26, C-27), 0.99 (d, 3H, J = 4.8 Hz, CH-CH3, C-21), 5.41 (dd, 1H, J = 3.2, 
2.3 Hz, H-6), 4.89 (m, 1H, H-3α) ppm. 
13C NMR (150.9 MHz, C5D5N, TMS): sugar 103.56 
(C-1”), 77.45 (C-5”), 75.37 (C-3”), 72.31 (C-2”), 70.28 (C-4”), 62.41 (C-6”); aromatic 
154.44 (C-4’), 135.00 (C-1’), 117.75 (C-3’, C-5’); sterol 140.21 (C-5), 122.78 (C-6), 56.81 
(C-14), 56.36 (C-17), 50.28 (C-9), 42.52 (C-13), 39.96 (C-12), 39.76 (C-24), 37.29 (C-1), 
32.07 (C-8), 28.65 (C-16), 28.53 (C-25), 24.52 (C-15), 24.18 (C-23), 22.97 (C-27), 22.72 (C-







IR: 3381, 3130, 2941, 2358, 1740, 1682, 1460 cm-1 
1H NMR (300 MHz, CDCl3): 0.64 (s, 3H, CH3), 0.83-0.85 (d, 6H, J = 6 Hz, CH3), 0.90-0.92 
(d, 3H, J = 6 Hz, CH3), 0.98 (s, 3H, CH3), 1.03-1.52 (m, 23H), 1.79-1.97 (m, 5H), 2.20-2.30 
(m, 2H), 2.49-2.50 (t, 2H, J = 4.2 Hz), 3.45-3.54 (m, 3H), 3.67-3.70 (t, 1H, J = 4.2 Hz), 3.75 
(d, 1H, J = 1.8 Hz), 3.97-4.01 (t, 1H, J = 6.9 Hz), 4.22 (s, 2H), 4.30-4.38 (m, 1H), 4.63-4.69 
(m, 1H), 5.33-5.43 (m, 1H), 5.43-5.45 (d, 1H, J = 6.9 Hz), 7.99 (s, 1H) ppm; 13C (75 MHz, 
CDCl3): 11.4 (C-18), 18.3, 18.8 (C-21), 20.3 (C-19), 22.1(C-26), 22.4 (C-27), 23.0, 23.6 (C-
23), 27.2, 27.5 (C-16), 27.6 (C-25), 31.1, 31.2, 35.0, 35.4, 35.8 (C-20), 36.4 (C-22), 38.1, 
38.7 (C-24), 49.3 (C-9), 55.4, 55.9 (C-17), 60.1, 68.1, 69.1, 73.0, 73.4 (C-3), 78.7, 78.9, 79.0, 
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